

GenCore version 5.1.6
 Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw mode!

Run on: November 5, 2004, 13:18:37 ; Search time 2544 Seconds
 (without alignments)
 557.662 Million cell updates/sec

Title: US-09-890-363-1

Perfect score: 30

Sequence: 1 gtaattcgccaaagaatgtttctgtc 30

Scoring table: IDENTITY_NUC

Gapop_10_0 , Gapext 1.0

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters:

2024102

Minimum DB seq length: 0

Maximum DB seq length: 75

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : GenEmbl:*

```
1: gb_ba:*
2: gb_htg:*
3: gb_in:*
4: gb_cm:*
5: gb_cv:*
6: gb_dat:*
7: gb Dh:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_ts:*
12: gb_sy:*
13: gb_un:*
14: gb_vl:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Description

Result No.	Score	Query	Match	Length	DB ID	Description
1	30	BD237979	AX032823	30	6 AX032823	BD237979 Formulati
2	30	100.0	BD237980	30	6 BD237980	BD237980 Formulati
3	26.8	89.3	BD237985	30	6 BD237985	BD237985 Formulati
C 4	26.8	89.3	AR41028	30	6 AR41028	AR41028 Sequence
C 5	26.8	89.3	AX032824	30	6 AX032824	AX032824 Sequence
C 6	26.8	89.3	AX032829	30	6 AX032829	AX032829 Sequence
C 7	26.8	89.3	AX032833	30	6 AX032833	AX032833 Sequence
C 8	26.8	89.3	BD237986	30	6 BD237986	BD237986 Formulati
9	17.2	57.3	AX032830	30	6 AX032830	AX032830 Sequence
C 10	17.2	57.3	AR41028	30	6 AR41028	AR41028 Sequence
C 11	17	57.7	BX547960	65	1 BX547960	BX547960 Arabidops
C 12	16.8	56.0	AX52037	50	6 AX52037	AX52037 Sequence
C 13	16.6	55.3	AX52631	50	6 AX52631	AX52631 Sequence
C 14	16.6	55.3	AX952011	49	6 AX952011	AX952011 Sequence
C 15	16.2	54.0	AX952044	49	6 AX952044	AX952044 Sequence
C 16	16.2	54.0	AX952605	49	6 AX952605	AX952605 Sequence
C 17	16.2	54.0	AX952338	49	6 AX952338	AX952338 Sequence
C 18	16.2	54.0	CQ531944	60	6 CQ531944	CQ531944 Sequence

RESULT 1	BD237979	LOCUS	BD237979 Formulations comprising antisense nucleotides to connexins.
		DEFINITION	BD237979 Formulations comprising antisense nucleotides to connexins.
		ACCESSION	BD237979
		VERSION	BD237979_1 GI:330407749
		KEYWORDS	JP 2002335377 A1.
		SOURCE	synthetic construct
		ORGANISM	synthetic construct
		ARTIFICIAL	artificial construct
		REFERENCE	(bases 1 to 30)
		AUTHORS	Becker, D.L. and Green, C.R.
		TITLE	Formulations comprising antisense nucleotides to connexins.
		JOURNAL	Patent: JP 200535377-A 1 22-OCT-2002;
		COMMENT	UNIVERSITY COLLEGE LONDON OS Artificial Sequence PN JP 202335377-A/1
		PD	PD 22-OCT-2002
		PF	PF 27-JAN-2000 JP 20000595711
		PR	PR 27-JAN-1999 NZ 333926,07-OCT-1999 NZ 500190 PI
		PC	DAVID LAURENCE BECKER, COLIN RICHARD GREEN A61K31/711, A61K9/06, A61K47/34, A61K47/46, PC A61K49/00
		PC	PC A61P1/02, A61P17/12, A61P25/00, A61P43/00, PC A61P43/00// C12N15/09
		CC	CC Description of Artificial Sequence: Oligonucleotide PH Key Location/Qualifiers FT Source 1..30 /organism='Artificial Sequence' Location/Qualifiers FT Source 1..30 /organism='synthetic construct' /mol_type='genomic DNA' /db_xref='taxon:32630'
		FEATURES	Query Match Best Local Similarity 100.0% Pred. No. 0.014; Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
		ORIGIN	OY 1 GTATTGGGCCAGAGAAATTGTTCTGTC 30

Db	1	GTAATTGGCCAAAGAAGAATTTCTGTC 30						
RESULT 2	APO32823	AX032823						
LOCUS	30 bp							
DEFINITION	Sequence 1 from Patent WO0044409.							
VERSION	1	1	1	1	1	1	1	1
KEYWORDS								
SOURCE								
ORGANISM								
FEATURES								
source								
ORIGIN								
Query Match	100.0%	Score 30;	DB 6;	Length 30;				
Best Local Similarity	100.0%	Pred. No. 0.014;						
- Matches	30;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;			
Query	1	GTAATTGGCCAAAGAAGAATTTCTGTC 30						
Db	1	GTAATTGGCCAAAGAAGAATTTCTGTC 30						
RESULT 3	BD37980	BD237980						
LOCUS	30 bp							
DEFINITION	Formulations comprising antisense nucleotides to connexins.							
ACCESSION	GI:3047750							
KEYWORDS								
SOURCE								
ORGANISM								
REFERENCE								
AUTHORS	Becker,D.L. and Green,C.R.							
TITLE	Patent: WO 004409-A 1 03-AUG-2000;							
JOURNAL								
COMMENT								
FEATURES								
source								
ORIGIN								
Query Match	100.0%	Score 30;	DB 6;	Length 30;				
Best Local Similarity	100.0%	Pred. No. 0.014;						
- Matches	30;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;			
Query	1	GTAATTGGCCAAAGAAGAATTTCTGTC 30						
Db	1	GTAATTGGCCAAAGAAGAATTTCTGTC 30						
RESULT 4	BD237985/c							
LOCUS	30 bp							
DEFINITION	Formulations comprising antisense nucleotides to connexins.							
ACCESSION	BD237985							
VERSION	GI:3047755							
KEYWORDS								
SOURCE								
ORGANISM								
REFERENCE								
AUTHORS	Becker,D.L. and Green,C.R.							
TITLE	Patent: WO 004409-A 1 03-AUG-2000;							
JOURNAL								
COMMENT								
FEATURES								
source								
ORIGIN								
Query Match	89.3%	Score 26.8;	DB 6;	Length 30;				
Best Local Similarity	93.3%	Pred. No. 0.39;						
- Matches	28;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;			
Query	1	GTAATTGGCCAAAGAAGAATTTCTGTC 30						
Db	1	GTAATTGGCCAAAGAAGAATTTCTGTC 30						
RESULT 5	BD237989/c							
LOCUS	30 bp							
DEFINITION	Formulations comprising antisense nucleotides to connexins.							
ACCESSION	BD237989							
VERSION	GI:3047759							
KEYWORDS								
SOURCE								
ORGANISM								
REFERENCE								
AUTHORS	Becker,D.L. and Green,C.R.							
TITLE	Patent: WO 004409-A 1 03-AUG-2000;							
JOURNAL								
COMMENT								
FEATURES								
source								
ORIGIN								
Query Match	89.3%	Score 26.8;	DB 6;	Length 30;				
Best Local Similarity	93.3%	Pred. No. 0.39;						
- Matches	28;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;			
Query	1	GTAATTGGCCAAAGAAGAATTTCTGTC 30						
Db	1	GTAATTGGCCAAAGAAGAATTTCTGTC 30						

PR 27-JAN-2000 JP 20000595711
PR 27-JAN-1989 NZ 331928-07-OCT-1993 NZ
DAVID LAURENCE BECKER, COLIN RICHARD GREEN
PC A61K31/711, A61K9/05, A61K9/10, A61K47/16, A61K47/34, A61K47/46, PC
PC A61P17/00, A61P17/02, A61P17/12, A61P17/16, A61P25/00, A61P29/00, A61P43/00,
PC A61P43/00//
CC C12N15/09, C12N15/00
Description of Artificial Sequence: Oligonucleotide FH
Key
Location/Qualifiers
FT source 1..30
FEATURES /organism='Artificial Sequence'
source Location/Qualifiers
1..30
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
ORIGIN

Query Match 57.3%; Score 17.2; DB 6; Length 30;
Best Local Similarity 73.3%; Pred. No. 8e+03; Indels 0; Gaps 0;
Matches 22; Conservative 0; Mismatches 8;

Qy 1 GTAAATTGCCGCAAGAAGATTTGGTTCTGTC 30
Db 1 GTAGTTACGACGGAGGATTGTTCTCGTC 30

RESULT 10
LOCUS AX032830 30 bp DNA linear PAT 21-SEP-2000
DEFINITION Sequence 8 from Patent WO0044409.
VERSION AX032830.1
KEYWORDS synthetic construct
ORGANISM artificial sequences.

REFERENCE Becker,D.L. and Green,C.R.
AUTHORS Formulations comprising antisense nucleotides to connexins
TITLE Patent: WO 0044409-A 8 01-AUG-2000;
JOURNAL BECKER DAVID LAURENCE (GB) ; UNTV LONDON (GB) ; GREEN COLIN RICHARD (NZ)
FEATURES Location/Qualifiers
source 1..30
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

ORIGIN

Query Match 57.3%; Score 17.2; DB 6; Length 30;
Best Local Similarity 73.3%; Pred. No. 8e+03; Indels 0; Gaps 0;
Matches 22; Conservative 0; Mismatches 8;

Qy 1 GTAAATTGCCGCAAGAAGATTTGGTTCTGTC 30
Db 1 GTAGTTACGACGGAGGATTGTTCTCGTC 30

RESULT 11
LOCUS AR411028 43 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 17 from patent US 6635475.
VERSION AR411028
KEYWORDS Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 43)
AUTHORS Hellmann,J.D.

Query Match 56.7%; Score 17; DB 6; Length 43;
Best Local Similarity 80.0%; Pred. No. 1e+04; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 5;

Qy 2 TAATTGCCGCAAGAAGATTTGGTTTC 26
Db 31 TACGTGAGAAAGAGATGTTTC 7

RESULT 12
LOCUS BX547960 65 bp DNA linear STS 02-JUL-2003
DEFINITION Arabidopsis thaliana transposon insertion STS SM_3_39244, sequence tagged site.
ACCESSION BX547960
VERSION BX547960.1 GI:32440780
KEYWORDS STS; STS, sequence tagged site.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Spermatophyta; Magnoliophyta; Streptophyta; Embryophyta; Tracheophyta; eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

Clarke,J.H., Bowles,B., Carter,J.J., Hart,D., McCullagh,B., Walsh,S.,
Langham,S., Legrys,C., Jones,J.D.G. and Bevan,M.
Unpublished
Clarke,J.H., Direct Submission
Submitted (02-JUL-2003) Clarke J.H., John Innes Centre, Colney Lane, Norwich, NR4 7UJ, UK
COMMENT AT denotes an activation tag dissociation transposon within a single line; ET an enhancer trap dissociation transposon, GT a gene trap dissociation transposon, MT a mis-expression enhancer trap dissociation transposon, SM a defective suppressor mutator transposon. -3 denotes a sequence derived from the 3' end of the transposon. -5 denotes a sequence derived from the 5' end of the transposon. BBSRC Garnet, ATIS project
On-line seed stock requests: <http://nasc.nott.ac.uk/> NASC stock code: N12555.

FEATURES Location/Qualifiers
1..65
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/variety="Columbia-0 NASC stock code N1092"
/db_xref="Taxon:3702"
/clone="AC02520"
/note="Derived from superpool 17.29 NASC code N40772"

ORIGIN

Query Match 56.0%; Score 16.8; DB 11; Length 65;
Best Local Similarity 90.0%; Pred. No. 1.e+04; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 2;

Qy 4 ATTGGGGCAGAGAGATTTG 23
Db 19 ATTGGGGCAGAGAGATTTG 38

RESULT 13
LOCUS AX952037/c 50 bp RNA linear PAT 08-JAN-2004
DEFINITION Sequence 94 from Patent WO03093504.

ACCESSION	AX952037	GI:	40782419	TITLE	Method for amplifying nucleic acids
KEYWORDS	synthetic construct			JOURNAL	WO 0309304-A 68 13-NOV-2003;
SOURCE	synthetic construct			FEATURES	Noxxon Pharma AG (DE)
ORGANISM	artificial sequences.			source	Location/Qualifiers
REFERENCE	Vater,A., Jarosch,F., Wattich,A. and Klussmann,S.				1..49
AUTHORS	Method for amplifying nucleic acids				/organism="synthetic construct"
JOURNAL	Patent : WO 0309304-A 94 13-NOV-2003 ;				/mol type="unassigned RNA"
FEATURES	Noxxon Pharma AG (DE)				/db_Xref="taxon:32630"
source	Location/Qualifiers				
	1..50				
	/organism="synthetic construct"				
	/mol type="unassigned RNA"				
	/db_Xref="taxon:32630"				
ORIGIN					

- Query Match 55.3% Score 16.6; DB 6; Length 50;
 Best Local Similarity 82.6%; Pred. No. 1.5e+04; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 4;

Qy	8 CGGGAGAAGAAATGTTCTGTC 30	Db	36 CGTCAGAACGAATCGTTCCTTC 14
----	----------------------------	----	------------------------------

RESULT 14	AX952631/C	AX952631	50 bp RNA	linear	PAT 08-JAN-2004
LOCUS	Sequence 186 from Patent WO03093472.				
DEFINITION					
ACCESSION	AX952631				
VERSION	AX952631.1	GI:40782971			
KEYWORDS					
SOURCE					
ORGANISM					
REFERENCE	Vater,A., Maasch,C., Jarosch,F., Bell,M., Helmling,S., Klussmann,S., Ruppert,T., Eschfeller,B., Mozyroud,E., Stark,S., Kluessmann,S., Ruppert,T., Schien,K., Bahrsen,G. and Gillen,C.				
AUTHORS	Cgrp binding nucleic acids				
JOURNAL	Patent : WO 03093472-A 186 13-NOV-2003 ;				
FEATURES	Gruenenthal GmbH (DE) ; Noxxon Pharma AG (DE)				
source	Location/Qualifiers				
	1..50				
	/organism="synthetic construct"				
	/mol type="unassigned RNA"				
	/db_Xref="taxon:32630"				
ORIGIN					

- Query Match 55.3% Score 16.6; DB 6; Length 50;
 Best Local Similarity 82.6%; Pred. No. 1.5e+04; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 4;

Qy	8 CGGCAGAAGAAATGTTCTGTC 30	Db	36 CGTCAGAACGAATCGTTCCTTC 14
----	----------------------------	----	------------------------------

RESULT 15	AX952011/C	AX952011	49 bp RNA	linear	PAT 08-JAN-2004
LOCUS	Sequence 68 from Patent WO03093504.				
DEFINITION					
ACCESSION	AX952011				
VERSION	AX952011.1 GI:40782393				
KEYWORDS					
SOURCE					
ORGANISM					
REFERENCE	Vater,A., Jarosch,F., Wattich,A. and Klussmann,S.				
AUTHORS					



GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model
Run on: November 5, 2004, 13:14:14 ; Search time 343 Seconds
(without alignments)
459.133 Million cell updates/sec

Title: US-09-890-363-1
Perfect score: 30
Sequence: 1 gtaattggccaaagaatgttttgc 30

Scoring table: IDNTTNUC
Gapop 10.0 , Gapext 1.0

Searched: 4124886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 4224225

Minimum DB seq length: 0
Maximum DB seq length: 75

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_23Sep04:*
1: Geneseqn1980s;*
2: Geneseqn1990s;*
3: Geneseqn2000s;*
4: Geneseqn2001as;*
5: Geneseqn2001bs;*
6: Geneseqn2002as;*
7: Geneseqn2002bs;*
8: Geneseqn2003as;*
9: Geneseqn2003bs;*
10: Geneseqn2003cs;*
11: Geneseqn2003ds;*
12: Geneseqn2004s;*

- Pred. NC is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB	ID	Description
1	30	100.0	30	3	AAA71646		Aaa71646 Connexin
2	26.8	89.3	30	3	AAA71647		Aaa71647 Connexin
c	3	26.8	89.3	30	3	AAA71652	Aaa71652 Connexin
c	4	17.2	57.3	30	3	AAA71653	Aaa71653 Chicken C
c	5	17	56.7	43	10	ADPF5088	Adi5088 Bacillus
c	6	16.6	55.3	50	11	ADM71609	Adm71609 CGRP-bind
c	7	16.6	55.3	50	11	ADM68129	Adm68129 Oligonucle
c	8	16.6	55.3	50	11	ADM67851	Adm67851 Rat alpha
c	9	16.2	54.0	49	11	ADM77161	Adm77161 CGRP-bind
c	10	16.2	54.0	49	11	ADM7583	Adm7583 CGRP-bind
c	11	16.2	54.0	49	11	ADM6758	Adm6758 Rat alpha
c	12	16.2	54.0	49	11	ADM68137	Adm68137 Oligonucle
c	13	16.2	54.0	49	11	ADM68170	Adm68170 Oligonucle
c	14	16.2	54.0	49	11	ADM68130	Adm68130 Oligonucle
c	15	16.2	54.0	49	11	ADM67825	Adm67825 Rat alpha
c	16	16.2	54.0	60	6	ABN35256	Abn35256 Human spl
c	17	16.2	54.0	70	2	AAV23259	Aav23259 Synthetic
c	18	15.8	52.7	27	3	AAZ87224	Aaz87224 Pinacada
c	19	15.8	52.7	41	6	AAV05625	Aav05625 Brassica
c	20	15.8	52.7	41	6	ABJ96067	Abj96067 Brassica
c	21	15.6	52.6	24	6	ABL41518	Abi41518 Primer GT

ALIGNMENTS

RESULT 1
AAA71646
ID AAA71646 standard; DNA; 30 BP.
XX AAA71646;
AC
XX 15-DEC-2000 (First entry)
XX DB Connexin 43 primer DNA #1.
XX Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;
vulnerary; antiinflammatory; dermatology; site-specific downregulation;
neuronal insult; brain; spinal cord; optic nerve; wound healing;
inflammation reduction; scar formation; epithelial basal cell division;
keratinization; skin rejuvenation; primer; ss.
XX Unidentified.
OS
XX WO200044409-A1.
XX PD 03-AUG-2000.
XX PP 27-JAN-2000; 2000WO-GB000238.
XX PR 27-JAN-1999; 99NZ-00333928.
PR 07-OCT-1999; 99NZ-00500190.
XX PA (UNL) UNIV COLLEGE LONDON.
XX Becker DL, Green CR;
XX WPI; 2000-491220/43.
PS Claim 9; Page 2; 64pp; English.

This invention describes a novel formulation (I) for use in therapeutic and/or cosmetic treatment, comprising at least one antisense polynucleotide (II) to a connexin protein together with a carrier or vehicle. The products of the invention have neuroprotective, vulnerary, antiinflammatory and dermatological activity. (II) is useful in a

formulation (I), which is administered to a site on or within a patient for the site specific downregulation of connexin protein expression. (I) is therefore specifically useful for reducing neuronal cell death resulting from neuronal insult to a specific site in the brain, spinal cord or optic nerve of a patient, for promoting wound healing resulting from trauma, burns or surgery and for reducing inflammation as a result of a wound or physical trauma of the brain, spinal cord or optic nerve and for decreasing scar formation. (I) containing (II) directed to connexin 43 or 31.1 is administered to regulate epithelial basal cell division and growth or to regulate outer layer keratinization, respectively, for skin rejuvenation or thickening for cosmetic or therapeutic purposes (I) downregulates connexin expression in a highly desirable site-specific manner. This sequence represents a connexin-43 directed oligonucleotide which is used in the method of the invention

Sequence 30 BP; 8 A; 4 C; 8 G; 10 T; 0 U; 0 Other;

Query Match 100.0%; Score 30; DB 3; Length 30;

* Best Local Similarity 100.0%; Pred. No. 0.0021; Indels 0; Gaps 0;

Matches 30; Conservative 0; Mismatches 0; DB

1 GTAAATTGCCGCAAGAAGATTGGTTCTGTCTC 30

1 GTAAATTGCCGCAAGAAGATTGGTTCTGTCTC 30

.

RESULT 2

AAA71647 standard; DNA; 30 BP.

XX ID AAA71647 standard; DNA; 30 BP.

AC AAA71647;

XX 15-DEC-2000 (first entry)

Connexin 43 primer DNA #2.

Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective; vulnearal; antiinflammatory dermatology; site-specific downregulation; neuronal insult; brain; spinal cord; optic nerve; wound healing; inflammation reduction; scar formation; epithelial basal cell division; keratinization; skin rejuvenation; primer; ss. Unidentified.

OS XX WO200044409-A1.

XX PD 03-AUG-2000.

XX PR 27-JAN-2000; 2000WO-GB000238.

XX PR 27-JAN-1999; 99NZ-00333928.

XX PR 07-OCT-1999; 99NZ-0050190.

XX PA (UNIL) UNIV COLLEGE LONDON.

XX PI Becker DL, Green CR;

XX DR WPI; 2000-491220/43.

XX PT New formulation for therapeutic and/or cosmetic treatment of neuronal cell death, inflammation and scar formation, comprises antisense polynucleotide to connexin protein.

XX PS Claim 9; Page 2; 6app; English.

XX DR WPI; 2000-491220/43.

PT New formulation for therapeutic and/or cosmetic treatment of neuronal cell death, inflammation and scar formation, comprises antisense polynucleotide to connexin protein.

CC This invention describes a novel formulation (I) for use in therapeutic and/or cosmetic treatment, comprising at least one antisense polynucleotide (II) to a connexin protein together with a carrier or vehicle. The products of the invention have neuroprotective, vulnerability and dermatological activity. (II) is useful in a antiinflammatory and dermatological formulation (I) which is administered to a site on or within a patient for the site-specific downregulation of connexin protein expression. (I) is therefore specifically useful for reducing neuronal cell death resulting from neuronal insult to a specific site in the brain, spinal cord or optic nerve of a patient, for promoting wound healing resulting for the site-specific downregulation of connexin protein expression. (I) is therefore specifically useful for reducing neuronal cell death

CC resulting from neuronal insult to a specific site in the brain, spinal cord or optic nerve of a patient, for promoting wound healing resulting from trauma, burns or surgery and for reducing inflammation as a result of a wound or physical trauma of the brain, spinal cord or optic nerve and for decreasing scar formation. (I) containing (II) directed to connexin 43 or 31.1 is administered to regulate epithelial basal cell division and growth or to regulate outer layer keratinization, respectively, for skin rejuvenation or thickening for cosmetic or therapeutic purposes (I) downregulates connexin expression in a highly desirable site-specific manner. This sequence represents a connexin-43 directed oligonucleotide which is used in the method of the invention

XX Sequence 30 BP; 6 A; 4 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 89.3%; Score 26.8; DB 3; Length 30;

Best Local Similarity 93.3%; Pred. No. 0.054; Indels 0; Gaps 0;

Matches 28; Conservative 0; Mismatches 2;

Qy 1 GTAAATTGCCGCAAGAAGATTGGTTCTGTCTC 30

Db 1 GTAAATTGCCGCAAGAAGATTGGTTCTGTCTC 30

RESULT 3

AAA71652/C standard; DNA; 30 BP.

XX ID AAA71652 standard; DNA; 30 BP.

AC AAA71652;

XX DT 15-DEC-2000 (first entry)

XX DB Connexin 43 primer DBsense DNA.

XX KW Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective; vulnerability; antiinflammatory; dermatology; site-specific downregulation; neuronal insult; brain; spinal cord; optic nerve; wound healing; inflammation reduction; scar formation; epithelial basal cell division; keratinization; skin rejuvenation; primer; ss. Unidentified.

XX PN WO200044409-A1.

XX PD 03-AUG-2000.

XX PR 27-JAN-2000; 2000WO-GB000238.

XX PR 27-JAN-1999; 99NZ-00333928.

XX PR 07-OCT-1999; 99NZ-0050190.

XX PA (UNIL) UNIV COLLEGE LONDON.

XX PI Becker DL, Green CR;

XX DR WPI; 2000-491220/43.

XX PT New formulation for therapeutic and/or cosmetic treatment of neuronal cell death, inflammation and scar formation, comprises antisense polynucleotide to connexin protein.

XX PS Example 1; Page 17; 64pp; English.

XX CC This invention describes a novel formulation (I) for use in therapeutic and/or cosmetic treatment, comprising at least one antisense polynucleotide (II) to a connexin protein together with a carrier or vehicle. The products of the invention have neuroprotective, vulnerability and dermatological activity. (II) is useful in a antiinflammatory and dermatological formulation (I) which is administered to a site on or within a patient for the site-specific downregulation of connexin protein expression. (I) is therefore specifically useful for reducing neuronal cell death resulting from neuronal insult to a specific site in the brain, spinal cord or optic nerve of a patient, for promoting wound healing resulting for the site-specific downregulation of connexin protein expression. (I) is therefore specifically useful for reducing neuronal cell death

CC from trauma, burns or surgery and for reducing inflammation as a result

CC of a wound or physical trauma of the brain, spinal cord or optic nerve
 CC and for decreasing scar formation. (I) containing (II) directed to
 CC connexin 43 or 31.1 is administered to regulate epithelial basal cell
 CC division and growth or to regulate outer layer keratinization,
 CC respectively. For skin rejuvenation or thickening for cosmetic or
 CC therapeutic purposes (I) downregulates connexin expression in a highly
 CC desirable site-specific manner. This sequence represents a connexin-43
 CC directed oligonucleotide which is used in the method of the invention
 XX

SQ Sequence 30 BP; 10 A; 10 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 89.3%; Score 26.8; DB 3; Length 30;

Best Local Similarity 93.3%; Prod. No. 0.054;

Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GATATTGGCGCAAGAAGATTGTTCTGTC 30

Db 30 GTATTGGCACGAGGAATTGTTCTGTGTC 1

RESULT 4

AAA71653 standard; DNA; 30 BP.

XX AAA71653;

XX 15-DEC-2000 (first entry)

XX Chicken connexin 43 primer DB1 DNA.

DE DB1 Connexin 43 primer DB1 DNA.

XX Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;

XX vulnerable; antiinflammatory; dermatology; site specific downregulation;

XX neuronal insult; brain; spinal cord; optic nerve; wound healing;

XX inflammation reduction; scar formation; epitelial basal cell division;

XX keratinization; skin rejuvenation; primer; chicken; ss.

OS Gallus sp.

XX WO20004409-A1.

PN 03-AUG-2000.

XX 27-JAN-2000; 2000WO-GB000238.

PP XX

PR 27-JAN-1999; 99NZ-00333928.

PR 07-OCT-1999; 99NZ-00500190.

XX (UNIL) UNIV COLLEGE LONDON.

PA Becker DL, Green CR;

XX Becker DL,

PI Example 1; Page 17; 64PP; English.

DR WPI; 2000-491220/43.

XX New formulation for therapeutic and/or cosmetic treatment of neuronal
 PT cell death, inflammation and scar formation, comprises antisense
 PT polynucleotide to connexin protein.

XX Example 1; Page 17; 64PP; English.

CC This invention describes a novel formulation (I) for use in therapeutic
 CC and/or cosmetic treatment, comprising at least one antisense
 CC polynucleotide (II), a connexin protein together with a carrier or
 CC vehicle. The products of the invention have neuroprotective, vulneary,
 CC antiinflammatory and dermatological activity. (II) is useful in a
 CC formulation (I), which is administered to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death
 CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing as a result
 CC of trauma, burns or surgery and for reducing inflammation as a result
 CC and for decreasing scar formation. (I) containing (II) directed to
 CC connexin 43 or 31.1 is administered to regulate epithelial basal cell

CC division and growth or to regulate outer layer keratinization,
 CC respectively, for skin rejuvenation or thickening for cosmetic or
 CC therapeutic purposes (I) downregulates connexin expression in a highly
 CC desirable site-specific manner. This sequence represents a connexin-43
 CC directed oligonucleotide which is used in the method of the invention
 XX

SQ Sequence 30 BP; 7 A; 5 C; 9 G; 9 T; 0 U; 0 Other;

Query Match 57.3%; Score 17.2; DB 3; Length 30;

Best Local Similarity 73.3%; Prod. No. 9.1e+02;

Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 GTAAATGGCGCAGAAGAGATTGTTCTGTC 30

Db 1 GTAGTACGACAGAGGAATTGTTCTGTC 30

RESULT 5

ADFS0888/C

ID ADF50888 standard; DNA; 43 BP.

XX XX AC ADF50888;

XX DT 12-FEB-2004 (first entry)

XX DE Bacillus subtilis yfhL DNA oligo homologous to sigW.

XX KW ECF; sigma factor; extracytoplasmic function;

XX autoregulatory promoter Px; sigW; Pw; detoxification; antimicrobial;

XX bacterial growth; replication; sigX.

XX Bacillus subtilis.

OS US6635475-B1.

PN XX PD 21-OCT-2003.

XX XX PP 28-JUL-2000; 2000US-00627746.

XX PR 30-JUL-1999; 99US-014466P.

XX (CORR) CORNELL RES FOUND INC.

XX PA XX

XX PI Helmann JD;

XX DR WPI; 2003-810568/76.

XX XX New Bacillus subtilis sigW gene encoding an extracytoplasmic function

XX alpha factor, useful for screening assays to identify potential

XX antibacterial agents.

XX Disclosure; SEQ ID NO 17; 18PP; English.

XX PS

XX This invention relates to novel *Bacillus subtilis* extracytoplasmic

CC function (ECF) sigma factors regulate their own

CC expression, accordingly the sigW operon is preceded by an autoregulatory

CC promoter named Px and likewise the sigW operon is autoregulated by the W-

CC dependent promoter Pw. A consensus based search approach was used to

CC identify further operons preceded by promoters similar in sequence to Pw

CC and hence recognised by SigW, such that SigW has been shown to control a

CC regulation of more than 30 genes including flotillin and epoxide hydrolase.

CC Specifically, SigW activates a large stationary phase regulon that

CC functions in detoxification and/or the production of antimicrobial

CC compounds that can be used to modulate bacterial growth and replication.

CC This oligonucleotide sequence is the *Bacillus subtilis* yfhL DNA that is

CC homologous to sigW of the invention.

XX SQ Sequence 43 BP; 14 A; 8 C; 8 G; 13 T; 0 U; 0 Other;

Query Match 56.7%; Score 17; DB 10; Length 43;

Best Local Similarity 80.0%; Prod. No. 1.2e+03;

Matches 20; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

CC sequences.
 XX Sequence 50 BP; 16 A; 9 C; 16 G; 9 T; 0 U; 0 Other;
 SQ Query Match Similarity 55.3%; Score 16.6; DB 11; Length 50;
 Best Local Similarity 82.6%; Pred. No. 1.8e+03; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 0;
 Qy 8 CGGCAAGAAAGAATTGTTCGTGTC 30
 Db 36 CGTCAGACGAAATGGTTCTGTC 14

RESULT 8
 ADM67851/C
 ID ADM67851 standard; RNA; 50 BP.
 XX
 AC ADM67851;
 XX DT 03-JUN-2004 (first entry)
 DE Rat alpha-D-CGRP binding oligonucleotide SEQ ID 94.
 XX nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.
 XX Rattus sp.
 OS WO2003093504-A1.
 XX PD 13-NOV-2003.
 XX PF 06-MAY-2003; 2003WO-EP004747.
 XX PR 06-MAY-2002; 2002DE-01020191.
 XX PA (NOXX-) NOXXON PHARMA AG.
 XX PI Vater A, Jarosch F, Wetlich A, Klussmann S;
 XX DR 2003-854487/79.
 XX PT Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.
 PS Example 12; SEQ ID NO 94; 262pp; German.
 XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the
 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adaptors are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids that bind to selected targets (aptamers). Potentially
 CC useful as therapeutic agents, e.g. antagonists of CGRP (calcitonin
 gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences. ADM6759-ADM67903 represent oligoribonucleotides capable of

CC binding to rat CGRP which are used to illustrate the method of the
 CC invention.
 XX Sequence 50 BP; 16 A; 9 C; 16 G; 0 T; 9 U; 0 Other;
 SQ Query Match Similarity 55.3%; Score 16.6; DB 11; Length 50;
 Best Local Similarity 82.6%; Pred. No. 1.8e+03; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 0;
 Qy 8 CGGCAAGAAAGAATTGTTCGTGTC 30
 Db 36 CGTCAGACGAAATGGTTCTGTC 14

RESULT 9
 ADM73616/C
 ID ADM73616 standard; RNA; 49 BP.
 XX
 AC ADM73616;
 XX DT 03-JUN-2004 (first entry)
 DE CGRP-binding ribo-oligonucleotide STAR-R02-15xx-B10.
 XX antagonist; CGRP; calcitonin gene-related peptide; amylin; amyloid;
 KW spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting;
 KW neurogenic inflammation; vasodilation; hypertension; hypertension;
 KW tachycardia; trigeminal afferent sensory activation;
 KW central nociceptive neuron; inflammatory pain; diabetes;
 KW gastric emptying; diabetic gastroparesis; polydysnia; ss.
 XX Synthetic.
 XX OS WO2003093472-A2.
 XX PN WO2003093472-A2.
 XX PD 13-NOV-2003.
 XX PR 06-MAY-2003; 2003WO-EP004746.
 XX PP 06-MAY-2002; 2002DE-01020188.
 XX PR 04-NOV-2002; 2002DE-01051246.
 XX PR (CHEF) GRUENENTHAL GMBH.
 XX PA (NOXX-) NOXXON PHARMA AG.
 XX PI Vater A, Maasch C, Jarosch F, Bell M, Helmung S, Eschgfeller B;
 PI Moerck E, Stark S, Klussmann S, Ruppert T, Schiene K, Bahnenberg G;
 PI Gillen C;
 XX DR 2003-854484/79.
 XX PT New antagonists of calcitonin gene-related peptide or amylin, useful for
 PT treating or preventing e.g. migraine or inflammation, are specific
 PT binding nucleic acids.
 XX Claim 15; SEQ ID NO 193; 263pp; German.
 XX This invention describes a novel antagonist of CGRP (calcitonin gene-
 related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-
 CC fluoro substituted on pyrimidine nucleotides) was incubated with
 CC biotinylated CGRP, for 3 hours at 37degC, then the incubation mixture
 CC applied to a matrix coated with streptavidin for 10 minutes at 37degC.
 CC The matrix was separated, washed with selection buffer and bound RNA
 CC recovered by elution with an excess of non-biotinylated CGRP. The bound
 CC RNA released this way was amplified and the selection procedure repeated
 CC for a total of 18 rounds, after which reverse transcription produced 192
 CC clones. One sequence was present in 168 of these clones. This sequence
 CC had a Kd of 10 nM and was used as starting sequence for preparation of
 CC optimised and truncated RNA aptamers or spiegelmers (RNM). Antagonists of
 CC CGRP, amylin and amyloid polypeptides are useful for treating and/or
 CC preventing: migraine, cluster headache, lack of appetite, nausea,
 CC vomiting, neurogenic inflammation (especially where mediated by other
 CC neuropeptides), vasodilation, hypo- or hyper-tension, tachycardia,

diseases that are associated with activation of trigeminal afferent sensory neurons and central nociceptive neurons (especially of the higher pain centres and including chronic inflammatory pain) and/or pain generally (chronic, acute, inflammatory, visceral or neuropathic), where CGRP is the target and hypertension, diabetes, disorders of gastric emptying, diabetic gastroparesis and polyuria, where amylin or amyloid peptides are the target. Antagonists that are nucleic acids are also useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to screen for other CGRP and amylin antagonists or agonists, as starting materials for rational drug design, for target validation and for studying CGRP or amylin function.

XX Sequence 49 BP; 16 A; 9 C; 16 G; 0 T; 8 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
Best Local Similarity 72.4%; Prd. No. 2.7e+03;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
Qy 2 TAATTCGCCAGAGATGTTCTCTTC 30
Db 42 TCATCGTCCCTAGCAGATGTTCTTC 14

RESULT 10
ADM73583 standard; RNA; 49 BP.
ID ADM73583
XX AC 03-JUN-2004 (first entry)
XX DE CGRP-binding ribo-oligonucleotide STAR-R02-12NM-E3.
XX antagonist; CGRP: calcitonin gene-related peptide; amylin; amyloid; spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting; neurogenic inflammation; vasodilation; hypotension; hypertension; tachycardia; trigeminal afferent sensory neuron activation; central nociceptive neuron; inflammatory pain; diabetes; gastric emptying; diabetic gastroparesis; polyuria; ss.
XX Synthetic.
PN WO200303472-A2.
XX PD 13-NOV-2003.
XX PP 06-MAY-2003; 2003WO-EP004746.
XX PR 04-NOV-2002; 2002DE-01020188.
XX PR 06-MAY-2002; 2002DE-01051246.
XX (CHEF) GRIELEMTHAL GMBH.
PA (NOXX-) NOXXON PHARMA AG.

Vater A, Maasch C, Jarosch F, Bell M, Helmung S, Eschgfeller B; Gillen C; Moyroud E, Stark S, Klussmann S, Ruppert T, Schiene K, Bahnenberg G; WPI; 2003-854484/79.
XX New antagonists of calcitonin gene-related peptide or amylin, useful for treating or preventing e.g. migraine or inflammation, are specific binding nucleic acids.
XX Claim 15; SEQ ID NO 160; 263pp; German.

XX This invention describes a novel antagonist of CGRP (calcitonin gene related peptide) amylin or an amyloid polypeptide. A library of RNA (2'-fluoro substituted on pyrimidine nucleotides) was incubated with biotinylated CGRP, for 3 hours at 37degC, then the incubation mixture applied to a matrix coated with streptavidin for 10 minutes at 37degC. The matrix was separated, washed with selection buffer and bound RNA recovered by elution with an excess of non-biotinylated CGRP. The bound

CC RNA released this way was amplified and the selection procedure repeated for a total of 18 rounds, after which reverse transcription produced 192 clones. One sequence was present in 168 of these clones. This sequence had a Kd of 10 nM and was used as starting sequence for preparation of optimised and truncated RNA aptamers or spiegelmers (RPs). Antagonists of CGRP, amylin and amyloid polypeptides are useful for treating and/or preventing: migraine, cluster headache, lack of appetite, nausea, vomiting, neurogenic inflammation (especially where mediated by other neuropeptides), vasodilation, hypo- or hyper-tension, tachycardia, diseases that are associated with activation of trigeminal afferent sensory neurons and central nociceptive neurons (especially of the higher pain centres and including chronic inflammatory pain) and/or pain generally (chronic, acute, inflammatory, visceral or neuropathic), where CGRP is the target and hypertension, diabetes, disorders of gastric emptying, diabetic gastroparesis and polyuria, where amylin or amyloid peptides are the target. Antagonists that are nucleic acids are also useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to screen for other CGRP and amylin antagonists or agonists, as starting materials for rational drug design, for target validation and for studying CGRP or amylin function.

CC SQ Sequence 49 BP; 15 A; 8 C; 16 G; 0 T; 10 J; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
Best Local Similarity 72.4%; Prd. No. 2.7e+03.
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTCGCCAGAGATGTTCTCTTC 30
Db 42 TCATCGTCCCTAGCAGATGTTCTTC 14

RESULT 11
ADM67858/C
ID ADM67858 standard; RNA; 49 BP.
XX AC ADN67858;
XX DT 03-JUN-2004 (first entry)
XX DE Rat alpha-D-CGRP binding oligonucleotide SEQ ID 101.
XX KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid; CGRP antagonist; calcitonin gene-related peptide; amylin; pain; drug design; primer; ss.
XX OS Rattus sp.
XX PN WO200303504-A1.
XX PR 13-NOV-2003.
XX XX 13-NOV-2003.
XX PI Vater A, Jarosch F, Wettich A, Klussmann S;
XX PA (NOXX-) NOXXON PHARMA AG.
XX DR WPI; 2003-854487/79.
XX PT Amplification of nucleic acid using two adaptors, useful for selection and preparation of aptamers, potential therapeutic agents, with all steps done in one vessel.
XX PS Example 12; SEQ ID NO 101; 262pp; German.

CC This invention describes a novel method for amplifying nucleic acids. The method comprises 1) preparing a target to be amplified, preferably RNA, having defined 5' and 3' sequences, separated by an intermediate sequence, 2) preparing a first adaptor (Ad1) of double stranded nucleic acid (especially one strand of RNA and the other DNA), where the 5'-end

of the DNA strand has an overhang at least partly complementary with the 5'-end of the target, 3) preparing a second adapter (Ad2) of double stranded nucleic acid, where the first strand has a 5'-phosphate residue on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at least partly complementary with the 3'-end of the target, the second strand also has a cleavage site which can generate a cleavage product that includes the complementary 3'-end of the second strand, 4) the adapters are ligated on the target, 5) reverse transcription is performed and optionally the second strand is synthesised. The products of the invention have antimigraine and analgesic activity. The method is especially used for selection and preparation of nucleic acids including L-nucleic acids, that bind to selected targets (aptamers), potentially useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin gene-related peptide) or amylin or their receptors, suitable for treatment of pain, migraine and other conditions, also as starting points for rational drug design, in screening for therapeutic compounds and for target validation. The method can be done in a single vessel, without purification of process intermediates and it can be applied to short sequences.

XX Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

SQ Query Match 54.0%; Score 16.2; DB 11; Length 49;
Best Local Similarity 72.4%; Prd. No. 2.7e+03;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
Qy 2 TAATGGCGCAAGAAATTGTTCTGC 30
Db 42 TCATCGTCCTAGCAGAATGTTCTTC 14

RESULT 14

ADM68130_C
ID ADM68130 standard DNA; 49 BP.

XX AC

XX

CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double stranded nucleic acid, where the first strand has a 5'-phosphate residue on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at least partly complementary with the 3'-end of the target, the second strand also has a cleavage site which can generate a cleavage product that includes the complementary 3'-end of the second strand, 4) the adapters are ligated on the target, 5) reverse transcription is performed and optionally the second strand is synthesised. The products of the invention have antimigraine and analgesic activity. The method is especially used for selection and preparation of nucleic acids including L-nucleic acids, that bind to selected targets (aptamers), potentially useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin gene-related peptide) or amylin or their receptors, suitable for treatment of pain, migraine and other conditions, also as starting points for rational drug design, in screening for therapeutic compounds and for target validation. The method can be done in a single vessel, without purification of process intermediates and it can be applied to short sequences.

XX SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
Best Local Similarity 72.4%; Prd. No. 2.7e+03;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
Qy 2 TAATGGCGCAAGAAATTGTTCTGC 30
Db 42 TCATCGTCCTAGCAGAATGTTCTTC 14

RESULT 15

ADM67825_C
ID ADM67825 standard RNA; 49 BP.

XX AC

XX

This invention describes a novel method for amplifying nucleic acids. The method comprises 1) preparing a target to be amplified, preferably RNA, having defined 5' and 3' sequences, separated by an intermediate sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic acid (especially one strand of RNA and the other DNA), where the 5'-end of the DNA strand has an overhang at least partly complementary with the 5'-end of the target, 3) preparing a second adapter (Ad2) of double

CC stranded nucleic acid, where the first strand has a 5'-phosphate residue on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at least partly complementary with the 3'-end of the target, the second strand also has a cleavage site which can generate a cleavage product that includes the complementary 3'-end of the second strand, 4) the adapters are ligated on the target, 5) reverse transcription is performed and optionally the second strand is synthesised. The products of the invention have antimigraine and analgesic activity. The method is especially used for selection and preparation of nucleic acids including L-nucleic acids, that bind to selected targets (aptamers), potentially useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin gene-related peptide) or amylin or their receptors, suitable for treatment of pain, migraine and other conditions, also as starting points for rational drug design, in screening for therapeutic compounds and for target validation. The method can be done in a single vessel, without purification of process intermediates and it can be applied to short sequences.

XX SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
Best Local Similarity 72.4%; Prd. No. 2.7e+03;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
Qy 2 TAATGGCGCAAGAAATTGTTCTGC 30
Db 42 TCATCGTCCTAGCAGAATGTTCTTC 14

XX DT 03-JUN-2004 (first entry)
XX DE Rat alpha-D-CGRP binding oligonucleotide SEQ ID 68.
XX KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
KW drug design; primer; ss.
XX OS Rattus sp.
XX PN WO2003033504-A1.
XX PD 13-NOV-2003.
XX PP 06-MAY-2003; 2003WO-EP004747.
XX PR 06-MAY-2002; 2002DE-01020191.
XX PA (NOXX-) NOXXON PHARMA AG.
XX PI Vater, A., Jarosch, F., Wettich, A., Klussmann, S.;
XX DR WPI; 2003-854487/99.
XX PT Amplification of nucleic acid using two adaptors, potential therapeutic agents, with all steps done in one vessel.
XX PS Example 12; SEQ ID NO 68; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The method comprises 1) preparing a target to be amplified, preferably RNA, having defined 5' and 3' sequences, separated by an intermediate sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic acid (especially one strand of RNA and the other DNA), where the 5'-end of the DNA strand has an overhang at least partly complementary with the 5'-end of the target, 3) preparing a second adapter (Ad2) of double

stranded nucleic acid, where the first strand has a 5'-phosphate residue on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at least partly complementary with the 3'-end of the target. The second strand also has a cleavage site which can generate a cleavage product that includes the complementary 3'-end of the second strand. 4) the adapters are ligated on the target. 5) reverse transcription is performed and optionally the second strand is synthesised. The products of the invention have antimigraine and analgesic activity. The method is especially used for selection and preparation of nucleic acids including L-nucleic acids, that bind to selected targets (aptamers), potentially useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin gene-related peptide) or amylin or their receptors, suitable for treatment of pain, migraine and other conditions, also as starting points for rational drug design, in screening for therapeutic compounds and for target validation. The method can be done in a single vessel, without purification of process intermediates and it can be applied to short sequences. ADM6759 ADM6793 represent oligoribonucleotides capable of binding to rat CGRP which are used to illustrate the method of the invention.

Sequence 49 BP; 15 A; 8 C; 16 G; 0 T; 10 U; 0 Other;

SQ Query Match 54.0%; Score 16.2; DB 11; Length 49;
Best Local Similarity 72.4%; Pred. No. 2.7e+03;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTCGGCAGAACATGTTCTGTC 30
Db 42 TCATCCTCACAGACCAATCCTTCTTC 14

Search completed: November 5, 2004, 15:52:39
Job time : 347 SECs



Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:29:37 ; Search time 71 Seconds
(without alignments)

300.333 Million cell updates/sec

Title: US-09-890-363-1

Perfect score: 30

Sequence: 1 gtaatggcgaaagaatttgttctgttc 30

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 824507 seqs, 355394441 residues

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 75

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents NA:*

1: /cgm2_6_ptodata/1/ina/5A_COMB.seq;*
2: /cgm2_6_ptodata/1/ina/5B_COMB.seq;*
3: /cgm2_6_ptodata/1/ina/6A_COMB.seq;*
4: /cgm2_6_ptodata/1/ina/6B_COMB.seq;*
5: /cgm2_6_ptodata/1/ina/PCITUS_COMB.seq;*
6: /cgm2_6_ptodata/1/ina/backfile1.seq;*

Pred. NC is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	17	56.7	43	4 US-09-627-746-17	Sequence 17, App1
C 2	15.8	52.7	41	3 US-08-813-207-94	Sequence 94, App1
C 3	15.8	52.7	41	3 US-09-614-253-94	Sequence 94, App1
C 4	15.8	52.7	47	4 US-09-671-317-510	Sequence 510, App1
C 5	15.2	50.7	75	3 US-09-310-310-25	Sequence 25, App1
C 6	14.8	49.3	47	4 US-09-671-317-596	Sequence 596, App1
C 7	14.8	49.3	73	1 US-08-314-001-42	Sequence 42, App1
C 8	14.8	49.3	73	1 US-08-313-585-42	Sequence 42, App1
C 9	14.8	49.3	73	1 US-08-434-425-42	Sequence 42, App1
C 10	14.8	49.3	73	2 US-08-437-667-42	Sequence 42, App1
C 11	14.8	49.3	73	3 US-08-906-955-42	Sequence 42, App1
C 12	14.8	49.3	73	3 US-08-945-909-42	Sequence 42, App1
C 13	14.8	49.3	73	3 US-09-395-002A-42	Sequence 42, App1
C 14	14.8	49.3	73	4 US-10-077-319-42	Sequence 42, App1
C 15	14.8	49.3	73	5 PCT-US96-06360-42	Sequence 42, App1
C 16	14.6	48.7	40	1 US-07-741-940-14	Sequence 14, App1
C 17	14.6	48.7	40	1 US-08-289-542A-14	Sequence 14, App1
C 18	14.6	48.7	40	1 US-08-452-655B-14	Sequence 14, App1
C 19	14.6	48.7	40	1 US-08-452-655B-14	Sequence 14, App1
C 20	14.6	48.7	40	4 US-08-449-731-14	Sequence 14, App1
C 21	14.6	48.7	40	4 US-09-270-757-29842	Sequence 29842, App1
C 22	14.4	48.0	57	4 US-19-215-850-56	Sequence 13, App1
C 23	14.4	48.0	61	3 US-09-237-584-13	Sequence 15, App1
C 24	14.2	47.3	27	3 US-09-186-170-15	Sequence 15, App1
C 25	14.1	46.7	24	4 US-09-542-866-15	Sequence 15, App1
C 26	14.1	46.7	24	4 US-10-116-288-15	Sequence 15, App1
C 27	14.1	46.7	24	4 US-10-116-288-15	Sequence 15, App1

ALIGNMENTS

RESULT 1
US-09-627-746-17/c
; Sequence 17, Application US/09627746
; Patent No. 6635475
; GENERAL INFORMATION:
; APPLICANT: Helmman, John
; TITLE OF INVENTION: Bacillus subtilis Extracytoplasmic Function Sigma Factor
; FILE REFERENCE: 10845-125
; CURRENT APPLICATION NUMBER: US/09-627-746
; CURRENT FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: US 60/146,466
; PRIOR FILING DATE: 1999-07-30
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 17
; LENGTH: 43
; TYPE: DNA
; ORGANISM: Bacillus subtilis
; US-09-627-746-17

Query Match Score 17; DB 4; Length 43;
Best Local Similarity 80.0%; Pred. No. 97;
Matches 20; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2 TATTCGGCGAGAAAGATTGTTC 26
Db 31 TACGTGAGAAAAGAGAAATGTTC 7

RESULT 2
US-08-813-507-94
; Sequence 94, Application US/08813507
; Patent No. 6114116
; GENERAL INFORMATION:
; APPLICANT: Lemieux, Bertrand
; ADDRESS: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS

COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: FASSEQ FOR Windows Version 2.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/105,390
 FILING DATE: Filed herewith
 CLASSIFICATION:
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 60/050,675
 FILING DATE: 25-JUN-97
 ATTORNEY/AGENT INFORMATION:
 NAME: Petithory, Joanne R.
 REGISTRATION NUMBER: P42,995
 REFERENCE/DOCKET NUMBER: 2000-0455,30
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650-324-0960
 TELEX:
 INFORMATION FOR SEQ ID NO: 25:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 75 base Pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 FEATURE:
 NAME/KEY: Coding Sequence
 LOCATION: 1..75
 OTHER INFORMATION:
 US-09-105-390-25

Query Match 50.7%; Score 15.2; DB 3; Length 75;
 Best Local Similarity 71.4%; Pred. No. 7.2e+02; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 GTAATGGGGAAAGAGAAATTGTTCTG 28
 Db 59 GGAATCTGCAAGGAGCATGCTACTG 32

RESULT 6
 US-09-671-317-596
 Sequence 596, Application US/09671317
 Patent No. 6528260
 GENERAL INFORMATION:
 APPLICANT: Blumenthal, Marta
 APPLICANT: Chumakov, Ilya
 APPLICANT: Bouquelert, Lydie
 APPLICANT: Cohen, Annick
 TITLE OF INVENTION: BIOTIPLIC MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
 FILE REFERENCE: 62 US3.CTP
 CURRENT APPLICATION NUMBER: US/09/671,317
 CURRENT FILING DATE: 2000-09-27
 PRIOR APPLICATION NUMBER: US 09/536,178
 PRIOR FILING DATE: 2000-03-23
 PRIOR APPLICATION NUMBER: PCT/IB00/00403
 PRIOR FILING DATE: 2000-03-24
 PRIOR APPLICATION NUMBER: US 60/126,269
 PRIOR FILING DATE: 1999-03-25
 PRIOR APPLICATION NUMBER: US 60/131,961
 PRIOR FILING DATE: 1999-04-30
 NUMBER OF SEQ ID NOS: 977
 SOFTWARE: Patent. pm
 SEQ ID NO 596
 LENGTH: 47
 TYPE: DNA
 ORGANISM: Homo Sapiens
 FEATURE:
 NAME/KEY: allele
 LOCATION: 24
 OTHER INFORMATION: 2-11-284 : polymorphic base A or G
 US-09-671-317-596

Query Match 49.3%; Score 14.8; DB 1; Length 73;
 Best Local Similarity 73.1%; Pred. No. 1.1e+03; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 AATGGCCAAAGAAGAAATTGTTCTG 28
 Db 55 AAATGCCAAAGAATGGTTCTGG 30

RESULT 8
US-08-43-585-42/C
Sequence 42, Application US/08433585
Patent No. 576356
GENERAL INFORMATION
APPLICANT: JENSEN, KIRK
APPLICANT: CHEN, HANG
APPLICANT: MORRIS, KEVIN
APPLICANT: STEPHENS, ANDREW
APPLICANT: GOLD, LARRY
TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: TISSUE
TITLE OF INVENTION: SELEX
NUMBER OF SEQUENCES: 235
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 8400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
COMPUTER: IBM pc compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/433,585
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/714,131
FILING DATE: 10-JUNE-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/536,428
FILING DATE: 11-JUNE-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/964,624
FILING DATE: 21-OCTOBER-1992
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30.4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-43-585-42

Query Match 49.3% Score 14.8; DB 1; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 7;

QY 3 AATTCGGGAAAGAATGTTCTG 28
Db 55 AAATCCAGCAAGAAATAGGTTCTGG 30

RESULT 10
US-08-437-667-42/C
Sequence 42, Application US/08437667
Patent No. 586406
GENERAL INFORMATION
APPLICANT: JENSEN, KIRK
APPLICANT: CHEN, HANG
APPLICANT: MORRIS, KEVIN
APPLICANT: STEPHENS, ANDREW
APPLICANT: GOLD, LARRY
TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: TISSUE
TITLE OF INVENTION: SELEX
NUMBER OF SEQUENCES: 235
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 8400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA

Query Match 49.3% Score 14.8; DB 1; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 7;

QY 3 AATTGGCGCAAGAGAATGTTCTG 28
Db 55 AAATCCAGCAAGAAATAGGTTCTGG 30

RESULT 9
US-08-434-425-42/C
Sequence 42, Application US/08434425
Patent No. 5789157
GENERAL INFORMATION
APPLICANT: JENSEN, KIRK
APPLICANT: CHEN, HANG
APPLICANT: MORRIS, KEVIN
APPLICANT: STEPHENS, ANDREW
APPLICANT: GOLD, LARRY

ZIP: 80111
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
 COMPUTER: IBM pc compatible
 OPERATING SYSTEM: MS-DOS
 SOFTWARE: WordPerfect 5.1
 CURRENT APPLICATION NUMBER: US/08/437,667
 FILING DATE:
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 07/714,131
 FILING DATE: 10-JUNE-1991
 ATTORNEY/AGENT INFORMATION:
 NAME: Barry J. Swanson
 REGISTRATION NUMBER: 33,215
 FILING DATE: 11-JUNE-1990
 REFERENCE/DOCKET NUMBER: NEX30-2
 APPLICATION NUMBER: 07/964,624
 FILING DATE: 21-OCTOBER-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Barry J. Swanson
 REGISTRATION NUMBER: 33,215
 FILING DATE: 11-JUNE-1990
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (303) 793-3433
 TELEFAX: (303) 793-3433
 INFORMATION FOR SEQ ID NO: 42:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 73 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: Single
 TOPOLOGY: linear
 US-08-437,667-42

Query Match Score 14.3; DB 2; Length 73;
 Best Local Similarity 73.1%; Pred. No. 1.1e+03;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 3 AATTGGCGAAGAAATGGTTCTG 28
 Db 55 ATAGCAGCAAGAAATAGGGTTCTG 30

RESULT 11
 US-08-906-955-42/c
 Sequence 42, Application US/08906955
 Patent No. 6013443
 GENERAL INFORMATION:
 APPLICANT: HEILIG, JOSEPH S.
 APPLICANT: GOLD, LARRY
 TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
 TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
 TITLE OF INVENTION: SELLEX
 NUMBER OF SEQUENCES: 240
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Swanson & Bratschun, L.L.C.
 STREET: 1400 E. Prentice Avenue, Suite 200
 CITY: Englewood
 STATE: Colorado
 COUNTRY: USA
 ZIP: 80111

COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
 COMPUTER: IBM pc compatible
 OPERATING SYSTEM: MS-DOS
 SOFTWARE: WordPerfect 6.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US96/06060
 FILING DATE: 01-MAY-1996
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/08/945,909
 FILING DATE: 03-MAY-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/434,425
 FILING DATE: 03-MAY-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/434,001
 FILING DATE: 03-MAY-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/437,667
 FILING DATE: 03-MAY-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/437,667
 FILING DATE: 03-MAY-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/433,585
 FILING DATE: 03-MAY-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Barry J. Swanson

REGISTRATION NUMBER: 33,215
 REFERENCE/DOCKET NUMBER: NEX30C-US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (303) 793-3333
 INFORMATION FOR SEQ ID NO: 42:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 73 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-909-42

Query Match Score 14.8; DB 3; Length 73;
 Best Local Similarity 73.1%; Prod. No. 1.1e+03 ;
 Matches 19; Indels 0; Gaps 0;

Qy 3 AATGGCGGAAGAAGAAATTGTTCTG 28
 Db 55 AATAGCAGCAAGAAATAAGGTTCGG 30

RESULT 13
 US-09-386-002A-42/C
 Sequence 42, Application US/09396002A
 Patent No. 6,376,474
 GENERAL INFORMATION:
 APPLICANT: HELIG, JOSEPH S.
 ATTORNEY/AGENT INFORMATION:
 GOLD, LARRY
 TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
 EXPONENTIAL ENRICHMENT: TISSUE SELEX
 NUMBER OF SEQUENCES: 240
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Swanson & Bratschun, L.L.C.
 STREET: 1745 Shea Center Drive, Suite 330
 CITY: Highlands Ranch
 STATE: Colorado
 COUNTRY: USA
 ZIP: 80129

COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: MS-DOS
 SOFTWARE: WordPerfect 8.0

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/10/077,319
 FILING DATE: 14-Feb-2002
 CLASSIFICATION: <Unknown>
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 09/396,002
 FILING DATE: 14-Sep-1999
 APPLICATION NUMBER: 07/714,131
 FILING DATE: 10-JUNE-1991
 APPLICATION NUMBER: 08/434,001
 FILING DATE: 05-MAY-1995
 APPLICATION NUMBER: 08/906,955
 FILING DATE: 05-AUGUST-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: Barry J. Swanson
 REGISTRATION NUMBER: 33,215
 REFERENCE/DOCKET NUMBER: NEX30-5/D
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (303) 268-0065
 INFORMATION FOR SEQ ID NO: 42:
 FILING DATE: 10-JUNE-1991
 APPLICATION NUMBER: 08/434,001
 FILING DATE: 05-MAY-1995
 APPLICATION NUMBER: 08/906,955
 FILING DATE: 05-AUGUST-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: Barry J. Swanson
 REGISTRATION NUMBER: 33,215
 REFERENCE/DOCKET NUMBER: NEX30-5/D
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (303) 268-0066
 INFORMATION FOR SEQ ID NO: 42:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 73 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 SEQUENCE DESCRIPTION: SEQ ID NO: 42:

US-10-077-319-42

Query Match Score 14.8; DB 4; Length 73;
 Best Local Similarity 73.1%; Prod. No. 1.1e+03 ;
 Matches 19; Indels 0; Gaps 0;

Qy 3 AATGGCGGAAGAAGAAATTGTTCTG 28
 Db 55 AATAGCAGCAAGAAATAAGGTTCGG 30

RESULT 15
 PCT-TS96-06060-42/C
 Sequence 42, Application PC/TUSS9606060
 GENERAL INFORMATION:
 APPLICANT: JENSEN, KIRK
 APPLICANT: CHEN, HANG

US-09-396-002A-42
 SEQUENCE DESCRIPTION: SEQ ID NO: 42:
 Query Match Score 14.8; DB 3; Length 73;
 Best Local Similarity 73.1%; Prod. No. 1.1e+03 ;

APPLICANT: MORRIS, KEVIN
APPLICANT: STEPHENS, ANDREW
APPLICANT: GOLD, LARRY
TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
NUMBER OF SEQUENCES: 240
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 9400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Wordperfect 5.1
APPLICATION NUMBER: PCT/US96/06060
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/714,131
FILING DATE: 10-JUNE-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/536,428
FILING DATE: 11-JUNE-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/964,624
FILING DATE: 21-OCTOBER-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/434,425
FILING DATE: 05-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/437,667
FILING DATE: 05-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/434,001
FILING DATE: 05-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/432,585
FILING DATE: 05-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30/PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US96-06060-42

Query Match 49.3%; Score 14.8; DB 5; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

3 AATTCGGCAAGAGAATTGTTCTG 28
||| ||| ||| ||| ||| |||
55 ATATGAGCAAGAAATAGGGTTCGG 30

Search completed: November 5, 2004, 17:15:09
Job time : 73 secs



GenCore version 5.1.6
 Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:47:02 ; Search time 344 Seconds

(without alignments)

469.545 Million cell updates/sec

Title: US-09-890-363-1

Perfect score: 30

Sequence: 1 gtaattggcaagaatgttgtatgtc 30

Scoring table: IDENTITY_NUC

GapOp 10.0 , GapExt 1.0

Searched: 3611042 seqs, 2692057975 residues

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 75

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing First 45 summaries

Database :

Published Applications NA.*

1: /cgn2_6_ptodata/1/pubpna/us07_pubcomb.seq*

2: /cgn2_6_ptodata/1/pubpna/pct_new_pub_seq.*

3: /cgn2_6_ptodata/1/pubpna/us06_new_pub_seq.*

4: /cgn2_6_ptodata/1/pubpna/us05_pubcomb.seq*

5: /cgn2_6_ptodata/1/pubpna/us07_new_pub_seq.*

6: /cgn2_6_ptodata/1/pubpna/pctus07_pubcomb.seq*

7: /cgn2_6_ptodata/1/pubpna/us08_new_pub_seq.*

8: /cgn2_6_ptodata/1/pubpna/us09_pubcomb.seq*

9: /cgn2_6_ptodata/1/pubpna/us09_pubcomb.seq*

10: /cgn2_6_ptodata/1/pubpna/us10_pubcomb.seq*

11: /cgn2_6_ptodata/1/pubpna/us10_new_pub_seq.*

12: /cgn2_6_ptodata/1/pubpna/us10_pubseq.*

13: /cgn2_6_ptodata/1/pubpna/us10_pubseq.*

14: /cgn2_6_ptodata/1/pubpna/us10c_pubcomb.seq.*

15: /cgn2_6_ptodata/1/pubpna/us10c_pubcomb.seq.*

16: /cgn2_6_ptodata/1/pubpna/us10d_pubcomb.seq.*

17: /cgn2_6_ptodata/1/pubpna/us10e_pubcomb.seq.*

18: /cgn2_6_ptodata/1/pubpna/us10_new_pub_seq.*

19: /cgn2_6_ptodata/1/pubpna/us11_new_pub_seq.*

20: /cgn2_6_ptodata/1/pubpna/uscc_new_pub_seq.*

21: /cgn2_6_ptodata/1/pubpna/uscc_pubcomb.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Match	Length	DB ID	Description
1	16.2	54.0	60	10	US-09-908-975-8004
2	15.8	52.7	41	14	US-10-043-573-94
c	3	15.8	52.7	47	US-10-294-934-10
4	15.4	51.3	43	15	US-10-032-585-7769
5	15.4	51.3	65	10	US-09-908-975-20222
c	6	15.2	50.7	73	US-10-037-632-51860
c	7	15.2	50.7	73	US-10-351-890-33
c	8	15	50.0	41	US-10-035-833A-2017
c	9	15	50.0	41	US-10-035-833A-4112
10	15	50.0	68	13	US-10-027-632-51852
11	15	50.0	68	13	US-10-027-632-51860
12	15	50.0	68	15	US-10-027-632-51852

No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Match	Length	DB ID	Description
1	16.2	54.0	60	10	US-09-908-975-8004
2	15.8	52.7	41	14	US-10-043-573-94
c	3	15.8	52.7	47	US-10-294-934-10
4	15.4	51.3	43	15	US-10-032-585-7769
5	15.4	51.3	65	10	US-09-908-975-20222
c	6	15.2	50.7	73	US-10-037-632-51860
c	7	15.2	50.7	73	US-10-351-890-33
c	8	15	50.0	41	US-10-035-833A-2017
c	9	15	50.0	41	US-10-035-833A-4112
10	15	50.0	68	13	US-10-027-632-51852
11	15	50.0	68	13	US-10-027-632-51860
12	15	50.0	68	15	US-10-027-632-51852

Sequence 51860, A

Sequence 68, App1

Sequence 1755, App

Sequence 596, App

Sequence 1549, App

Sequence 1577, App

Sequence 42, App1

Sequence 49, App1

Sequence 3912, App

Sequence 24143, App

Sequence 26971, App

Sequence 2622, App

Sequence 56, App1

Sequence 199, App

Sequence 48, App1

Sequence 2, App1

Sequence 1219, App

Sequence 12670, App

Sequence 13912, App

Sequence 15633, App

Sequence 22515, App

Sequence 1807, App

Sequence 28469, App

Sequence 4, App1

Sequence 5, App1

Sequence 6, App1

Sequence 7, App1

Sequence 15, App1

Sequence 12253, App

Sequence 16, App1

Sequence 17, App1

Sequence 14, App1

RESULT 1

US-09-908-975-8004

Publication No. US003016593A1

Publication, Avi Shoshan

Wasserman, Alon

Mintz, Eli

Minz, Liat

Faigler, Simchon

Title of Invention: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTOME AND SPLICE

Title of Invention: THAT POPULATE A TRANSCRIPTOME

FILE REFERENCE: 36688-0005

CURRENT APPLICATION NUMBER: US/09/908,975

PRIOR APPLICATION NUMBER: 2001-07-20

PRIOR FILING DATE: 2001-05-02

PRIOR APPLICATION NUMBER: US 60/1287,724

PRIOR FILING DATE: 2001-07-28

NUMBER OF SEQ ID NOS: 32337

SOFTWARE: PatentIn version 3.0

SEQ ID NO: 8004

LENGTH: 60

TYPE: DNA

ORGANISM: Homo sapiens

US-09-908-975-8004

Query Match

Best Local Similarity

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels 0;

Score 16.2;

DB 10;

DB 9+0.3;

Gaps 0;

Mismatches 3;

Indels

RESULT 2
US-10-043-573-94
Sequence 94, Application US/10043573
Publication No. US20030032025A1
GENERAL INFORMATION:
APPLICANT: Lemire, Benoit S.
Landry, Ronald J.
Sabolsky, Brissica Polymorphisms
TITLE OF INVENTION: Brissica Polymorphisms
NUMBER OF SEQUENCES: 173
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ for Windows Version 2.0

CURRENT APPLICATION DATE:
APPLICATION NUMBER: US/10/043, 573
FILING DATE: 09-Jan-2002
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/813, 507
FILING DATE: 07-MAR-1997
APPLICATION NUMBER: US 60/032, 069
FILING DATE: 02-DEC-1996

ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37, 505
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415 576-0200
TELEX: <Unknown>
FAX: 415 576-0200

INFORMATION FOR SEQ ID NO: 94:
SEQUENCE CHARACTERISTICS:
LENGTH: 41 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 94:
US-10-043-573-94

Query Match 52.7%; Score 15.8; DB 14; Length 41;
Best Local Similarity 74.1%; Pred. No. 4e+03; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 7; InDelS 6; Gaps 0;

Qy 4 ATTGGGGAGAAAGATTGTTCTTC 30
Db 12 ATGGGTGATGGATTGTTCTATC 38

RESULT 3
US-10-294-934-510/C
Sequence 510, Application US/10294934
Publication No. US2004003831A1
GENERAL INFORMATION:
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
APPLICANT: Bougueleret, Lydie
APPLICANT: Cohen, Annick

TITLE OF INVENTION: BIALLERIC MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
FILE REFERENCE: 62.US.DIV
CURRENT APPLICATION NUMBER: US/10/294, 934
CURRENT FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: US 09/671, 317
PRIOR FILING DATE: 2000-09-27

RESULT 4
US-10-294-934-510
Query Match 52.7%; Score 15.8; DB 16; Length 47;
Best Local Similarity 74.1%; Pred. No. 4.1e+03; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 7; InDelS 6; Gaps 0;

Qy 3 AATTGGCCAGAGAGATTGTTCTGT 29
Db 30 AATTCYGTAGAGATTCCTGCCT 4

RESULT 4
US-10-294-934-510
Query Match 52.7%; Score 15.8; DB 16; Length 47;
Best Local Similarity 74.1%; Pred. No. 4.1e+03; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 7; InDelS 6; Gaps 0;

Qy 3 AATTGGCCAGAGAGATTGTTCTGT 29
Db 30 AATTCYGTAGAGATTCCTGCCT 4

RESULT 5
US-10-032-585-1769
Sequence 1769, Application US/10032585
Publication No. US20030180953A1
GENERAL INFORMATION:
APPLICANT: Terry, Roemer D.
APPLICANT: Bo, Jiang
APPLICANT: Charles, Boone
APPLICANT: Howard, Bussey
TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
FILE REFERENCE: 10182-005-999
CURRENT APPLICATION NUMBER: US/10/032, 585
CURRENT FILING DATE: 2001-12-30
NUMBER OF SEQ ID NOS: 8000
SOFTWARE: PatentIn version 3.1
SEQ ID NO: 1769
LENGTH: 43

Query Match 51.3%; Score 15.4; DB 15; Length 43;
Best Local Similarity 76.0%; Pred. No. 6e+03; Indels 0; Gaps 0;

Qy 5 TTGGCCAGAGATGTGTTCTGT 29
Db 1 TTACGCAAGACATGAACTAT 25

RESULT 5
US-10-032-585-1769
Sequence 1769, Application US/10032585
Publication No. US20030180953A1
GENERAL INFORMATION:
APPLICANT: SHOSHAN, Avi
APPLICANT: WASSERMAN, Alon
APPLICANT: MINIZ, Eli
APPLICANT: FAIGNER, Simchon
TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTOME AND SPLICE
FILE REFERENCE: 36688-0005
CURRENT APPLICATION NUMBER: US/09/908, 975

CURRENT FILING DATE: 2001-07-20
 PRIOR APPLICATION NUMBER: US 60/287,724
 PRIOR FILING DATE: 2001-05-02
 PRIOR APPLICATION NUMBER: US 60/221,607
 PRIOR FILING DATE: 2000-07-28
 NUMBER OF SEQ ID NOS: 32337
 SOFTWARE: PatentIn version 3.0
 SEQ ID NO: 30222
 LENGTH: 65
 TYPE: DNA
 ORGANISM: *Mus musculus*
 US-09-908-975-30222

Query Match 51.3%; Score 15.4; DB 10; Length 65;
 Best Local Similarity 76.0%; Pred. No. 6.6e+03 ;
 Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 2 TAATGGCGAAAGAGAATTGTTTC 26
 Db 16 TAACTGGACAGGGAGATCGRttTC 40

RESULT 6

US-10-403-337-33/c

Sequence 33, Application US/10403337
 Publication No. US20010215948A1

GENERAL INFORMATION:
 APPLICANT: Kaleko, Michael
 INVENTION: Nemew, Glen R.

APPLICANT: Smith, Theodore
 INVENTION: Stevenson, Susan C.

TITLE OF INVENTION: Fiber Shaft Modifications for Efficient Targeting

CURRENT APPLICATION NUMBER: US/10/403,337
 CURRENT FILING DATE: 2003-03-27

PRIOR FILING DATE: 10/351,890

PRIOR APPLICATION NUMBER: 6/350,388

PRIOR FILING DATE: 2002-01-24

PRIOR APPLICATION NUMBER: 60/391,967

PRIOR FILING DATE: 2002-06-26
 NUMBER OF SEQ ID NOS: 72

SOFTWARE: PatentIn version 3.0

SEQ ID NO: 33
 LENGTH: 73

TYPE: DNA
 ORGANISM: Artificial Sequence

FEATURE:
 OTHER INFORMATION: amplification primer

US-10-351-590-33

Query Match 50.7%; Score 15.2; DB 15; Length 73;
 Best Local Similarity 71.4%; Pred. No. 8.4e+03 ;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATGGCGAAAGAGAATTGTTTC 29

Db 59 TAACTGAGATAAAGATCCTTGTGT 32

RESULT 7

US-10-351-890-33/c

Sequence 33, Application US/10351890
 Publication No. US20040002060A1

GENERAL INFORMATION:
 APPLICANT: Kaleko, Michael
 INVENTION: Nemew, Glen R.

TITLE OF INVENTION: Fiber Shaft Modifications for Efficient Targeting

CURRENT APPLICATION NUMBER: US/10/351,890

CURRENT FILING DATE: 2003-01-28

NUMBER OF SEQ ID NOS: 7669

SOFTWARE: PatentIn version 3.2

SEQ ID NO: 4612
 LENGTH: 41

TYPE: DNA
 ORGANISM: Homo sapiens

US-10-035-833A-4612

Query Match 50.0%; Score 15; DB 16; Length 41;
 Best Local Similarity 72.0%; Pred. No. 9e+03 ;
 Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 2 TAATGGCGAAAGAGAATTGTTTC 26

Db 38 TATTACGCAATGAWTTTTTC 14

RESULT 8

US-10-035-833A-2017/c

Sequence 2017, Application US/10035833A
 Publication No. US2004072156A1

GENERAL INFORMATION:
 APPLICANT: Nakamura, Yuho
 INVENTION: Sekine, Akihiro

APPLICANT: Saito, Osamu
 INVENTION: Iida, Aritoshi

TITLE OF INVENTION: Detection of Genetic Polymorphisms
 FILE REFERENCE: F0RS-05904

CURRENT APPLICATION NUMBER: US/10/035,833A
 CURRENT FILING DATE: 2001-12-27

NUMBER OF SEQ ID NOS: 7669

SOFTWARE: PatentIn version 3.2

SEQ ID NO: 2017
 LENGTH: 41

TYPE: DNA
 ORGANISM: Homo sapiens

US-10-035-833A-2017

Query Match 50.7%; Score 15.2; DB 16; Length 41;
 Best Local Similarity 71.4%; Pred. No. 8.4e+03 ;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATGGCGAAAGAGAATTGTTTC 26

Db 38 TATTACGCAATGAWTTTTTC 14

RESULT 9

US-10-035-833A-4612/c

Sequence 4612, Application US/10035833A
 Publication No. US2004072156A1

GENERAL INFORMATION:
 APPLICANT: Nakamura, Yuho
 INVENTION: Sekine, Akihiro

APPLICANT: Iida, Aritoshi
 INVENTION: Saito, Osamu

TITLE OF INVENTION: Detection of Genetic Polymorphisms

FILE REFERENCE: F0RS-06904

CURRENT APPLICATION NUMBER: US/10/035,833A
 CURRENT FILING DATE: 2001-12-27

NUMBER OF SEQ ID NOS: 7669

SOFTWARE: PatentIn version 3.2

SEQ ID NO: 4612
 LENGTH: 41

TYPE: DNA
 ORGANISM: Homo sapiens

US-10-035-833A-4612


```

; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/195,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-08
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 51860
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51860

Query Match      50.0%; Score 15; DB 15; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e+04; Matches 1; Mismatches 1; Indels 0; Gaps 0;
Job time : 347 secs

Qy   2 TAATTGGCCAGAAAGAATTGTTTC 26
Db   10 TAATAGGGATAAGAACSATTC 34

RESULT 14
US-10-125-994A-68
Sequence 68, Application US10125994A
Publication No. US20030203427A1
GENERAL INFORMATION:
; APPLICANT: Koike, Chihiro
; TITLE OF INVENTION: ALPHA 1, 3-GALACTOSYLTRANSFERASE GENE AND PROMOTER
; FILE REFERENCE: 206779
CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: PCT/US00/29139
PRIOR APPLICATION NUMBER: US 60/227,951
; PRIOR FILING DATE: 2000-09-25
; PRIOR FILING DATE: 1999-10-22
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO: 68
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for identifying murine exons 2 and 3
US-10-125-994A-68

Query Match      49.3%; Score 14.8; DB 15; Length 35;
Best Local Similarity 73.1%; Pred. No. 1.1e+04; Matches 1; Mismatches 0; Indels 0; Gaps 0;
Job time : 347 secs

Qy   5 TGGGGCAGAAAGAATTGTTCTGTC 30
Db   6 TGGGGCAGAAAGAATTGTTCTGAC 31

RESULT 15
US-10-032-585-1755/C
; Sequence 1755, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
```



GenCore version 5.1.6
Copyright (c)1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:28:19 (without alignments)
472.221 Million cell updates/sec

Title: US-09-890-363-1
Perfect score: 30
Sequence: 1 gtaattggcaagaatgttttgttc 30

Scoring table: IDENTITY_NUC
Gapov 10.0 , Gapext 1.0

*searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0
Maximum DB seq length: 75
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST*
1: 9b_est1: *
2: 9b_est2: *
3: 9b_htc: *
4: 9b_est3: *
5: 9b_est4: *
6: 9b_est5: *
7: 9b_est6: *
8: 9b_gss1: *
9: 9b_gss2: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query	Score	Match	Length	DB ID	Description
c 1	A7J99937	17.4	58.0	37	8 A2333195	A2333195 1M006G09 T87927 Ye08C07.r1
c 2	A7J99937	15.6	52.0	70	1 A1024389	A1024389 r8421a45
c 3	A7J99937	15.4	51.3	62	1 A4591826	A4591826 v14e12.r
c 4	A7J99937	15.4	51.3	67	1 CDB81194	CDB81194 F1..10K17
c 5	A7J99937	15.4	51.3	70	8 BFB865903	BFB865903 SALK1000
c 6	A7J99937	15.4	51.3	70	8 BFB865903	AU01405 AU014056
c 7	A7J99937	15.4	51.3	75	1 BFB09815	BFB09815 SALK_0561
c 8	A7J99937	15.2	50.7	39	9 AJ799937	AJ799937 Arabidops
c 9	A7J99937	15.2	50.7	49	9 AJ799937	AJ799937 Arabidops
c 10	A7J99937	15.2	50.7	74	1 AA704411	AA704411 zj21n01.5
c 11	A7J99937	15.2	50.7	74	1 CPB53347	CPB53347 pSMCD08xh
c 12	A7J99937	15	50.0	41	8 BFB56306	BFB56306 SALK_0799
c 13	A7J99937	15	50.0	58	1 AAS54039	AAS54039 nk95j3.s
c 14	A7J99937	15	50.0	75	4 BMF41762	BMF41762 fw52e08.y
c 15	A7J99937	14.8	49.3	39	2 BE335115	BE335115 601231231
c 16	A7J99937	14.8	49.3	44	8 AZE22559	AZE22559 1M045P24
c 17	A7J99937	14.8	49.3	59	1 BZT69592	BZT69592
c 18	A7J99937	14.8	49.3	60	1 AA388795	AA388795 vb25c07.r
c 19	A7J99937	14.8	49.3	61	1 A1S29969	A1S29969 w185b06.x
c 20	A7J99937	14.6	49.3	63	7 N23930	N23930 y8912.s1
c 21	A7J99937	14.6	48.7	52	2 BF613547	BF613547 NF057G03D
c 22	A7J99937	14.6	48.7	54	8 BH812420	BH812420 SALK_0617
c 23	A7J99937	14.6	48.7	62	4 CG667820	CG667820 OST45327
c 24	A7J99937	14.6	48.7	64	4 B1097338	B1097338 SWOv3NCAM

ALIGNMENTS

c 25	14.6	48.7	67	9 CC795622	CC795622 SALK_0875
c 26	14.6	48.7	69	6 CD028582	CD028582 mgns007xf
c 27	14.6	48.7	72	4 BJ057828	BJ057828
c 28	14.6	48.7	73	5 BX97533	BX97533 BX697533
c 29	14.6	48.7	73	5 CB832531	CB832531 SWbmcECAV
c 30	14.6	48.7	73	6 CG495277	CG495277 CSN4591
c 31	14.6	48.7	74	7 CN862695	CN862695 0009034AL
c 32	14.6	48.7	75	2 AW47813	AW47813 2824477.3
c 33	14.4	48.0	42	1 AU268709	AU268709 AU268709
c 34	14.4	48.0	45	6 CA967668	CA967668 CCIL03A0
c 35	14.4	48.0	68	1 AV52289	AV52289 AV852289
c 36	14.4	48.0	68	8 A222150	A222150 1006030CO
c 37	14.4	48.0	73	5 BU870927	BU870927 Q021E02 P
c 38	14.4	48.0	74	8 AZ576247	AZ576247 ASY-TD145
c 39	14.4	48.0	75	6 CD744649	CD744649 KB17 A1.2
c 40	14.2	47.3	37	4 BJ066419	BJ066419
c 41	14.2	47.3	50	8 BZ664415	BZ664415 SALK_071.0
c 42	14.2	47.3	50	8 BZ664418	BZ664418 SALK_071.1
c 43	14.2	47.3	52	8 BZ694935	BZ694935 TE-389-3
c 44	14.2	47.3	54	2 BF450060	BF450060 msa446c07.
c 45	14.2	47.3	54	8 BZ761965	BZ761965 SALK_0837

was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA Polymerase and T4 Polynucleotide kinase. Adaptor Oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMPD2 (gi|47321141|gb|AFI29072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptorized mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent *E. coli* X10-Gold (Stratagene) cells and selected for ampicillin resistance.

ORIGIN

Query Match 58.0%; Score 17.4; DB 8; Length 37;
 • Best Local Similarity 77.8%; Pred. No. 5.7e+03;
 • Matches 21; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Query Match 52.0%; Score 15.6; DB 7; Length 70;
 • Best Local Similarity 70.0%; Pred. No. 3.9e+04;
 • Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

ORIGIN

Query Match 52.0%; Score 15.6; DB 7; Length 70;

• Best Local Similarity 70.0%; Pred. No. 3.9e+04;
 • Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Query Match 1 GTAATGGCCAAGAGAAATTGTTCTGTC 30
 • Best Local Similarity 70.0%; Pred. No. 3.9e+04;
 • Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Query Match 1 GAAATGGATAAGATACTGTGTC 60
 • Best Local Similarity 70.0%; Pred. No. 3.9e+04;
 • Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

RESULT 3

AL024389

LOCUS r8421a5

DEFINITION Beddington mouse dissected endoderm Mus musculus cDNA

VERSION r8424389

KEYWORDS EST.

ORGANISM Mus musculus (house mouse)

MUS MUSCULUS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

REFERENCE Harrison, S.M., Dunwoodie, S.L., Arkeil, R.M., Lehrach, H. and Beddington, R.S.

AUTHORS Isolation of novel tissue-specific genes from cDNA libraries representing the individual tissue constituents of the gastrulating mouse embryo

JOURNAL Development 121 (8), 2479-2489 (1995)

MEDLINE 95401865

PUBMED 7671812

COMMENT Contact: Wiles,M.; Lehrach,H. and Avner,P.

EBI Mouse Transcript Mapping Consortium

Genoscope - CNS

2, rue Gaston Crèmeux, 91000 Evry, France

Email: pavne@pasteur.fr

clone available from Ressourcenzentrum, Heubnerweg 6,

Berlin, Germany. Web site <http://www.rzpd.de>

Seq primer: CGGGCGGATTCGGGT;

High quality sequence only submitted.

Vector: pSPORT1; site_1: NotI; site_2: SalI;

Cloned unidirectionally.

Dissected endoderm 7.5 days.

Average insert size: 1.2 kb (range: 0.2 - 2.4 kb).

Location/Qualifiers

1..62

/organism="Mus musculus"

/mol_type="mRNA"

/strain="C57BL/6 x DBA"

/db_xref="taxon:10090"

/clone="128-7J11"

/tissue_type="dissected endoderm"

/dev_stage="7.5 dpc"

/clone.lib="Beddington"

mouse dissected endoderm"

/note="Vector: pSPORT1; Site_1: NotI; Site_2: SalI; Cloned unidirectionally." High quality sequence only submitted." Average insert size: 1.2 kb (range: 0.2 - 2.4 kb)"

ORIGIN

Query Match 51.3%; Score 15.4; DB 1; Length 62;

• Best Local Similarity 76.0%; Pred. No. 4.7e+04;

• Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 1 GTAATGGCCAAGAGAAATTGTT 25

FEATURES source

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="GDB:485421"

/clone.xref="taxon:9606"

/clone.name="IMAGE:117132"

/sex="male"



Copyright (c) 1993 - 2004 Compugen Ltd.	GenCore version 5.1.6
W protein - protein search, using sw model	
run on:	November 5, 2004, 20:41:18 ; Search time 43 Seconds (without alignments) 157.312 Million cell updates/sec
title:	US-09-882-434A-1
perfect score:	551
sequence:	1 MASTKLEFFSVITVMMIAMA..... FGSARACNPFGMWSIFIQC 102
scoring table:	BLOSUM62
Gapop:	10.0 , Gapext 0.5

maximum DB seq length: 2000000000

cost-processing: Minimum Match 0%

Listing first 45 summaries

database : Issued_Patents_AA: * /55

2: /cgn2_6/ptodata/1/iaa/5B

4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

result	Query No.	Score	Match	Length	DB ID	Description
1	75.5	13.7	486	4	US-08-169-613A2	Sequence 2, Appli
	75.5	13.7	486	4	US-08-622-191-8	Sequence 8, Appli
2	74.5	13.5	486	1	US-07-872-678A-48	Sequence 48, Appli
3	74.5	13.5	908	4	US-08-714-741-44	Sequence 44, Appli
4	74.5	12.9	1280	4	US-09-672-810-2	Sequence 2, Appli
5	71	12.9	1280	4	US-09-672-810-4	Sequence 4, Appli
6	71	12.9	1283	4	US-09-672-810-4	Sequence 30166, A
7	7	12.7	365	4	US-09-552-11A-30166	Sequence 30166, A
8	69	12.5	491	4	US-09-248-796A-17049	Sequence 17049, A
9	69	12.5	1280	4	US-09-672-810-7	Sequence 7, Appli
10	69	12.5	1280	4	US-09-672-725C-4	Sequence 4, Appli
11	69	12.5	1280	4	US-10-044-671-2	Sequence 2, Appli
12	69	12.5	1281	4	US-09-672-725C-2	Sequence 23, Appli
13	69	12.5	1281	4	US-09-672-725C-23	Sequence 25, Appli
14	69	12.5	1281	4	US-09-672-725C-25	Sequence 27, Appli
15	69	12.5	1281	4	US-09-672-725C-27	Sequence 19, Appli
16	68	12.3	1280	2	US-08-583-276-19	Sequence 2, Appli
17	68	12.3	1280	2	US-08-552-47-2	Sequence 2, Appli
18	68	12.3	1280	3	US-09-316-167-2	Sequence 2, Appli
19	68	12.3	1280	4	US-09-767-594-2	Sequence 5, Appli
20	68	12.3	1280	4	US-09-672-810-5	Sequence 5, Appli
21	68	12.3	1280	4	US-09-397-233-2	Sequence 7, Appli
22	68	12.3	1280	4	US-09-672-725C-7	Patent No. 5,206552
23	68	12.3	1280	6	5206552-4	Sequence 19374, A
24	67.5	12.3	312	4	US-09-252-991A-19374	Sequence 4648, Ap
25	67.5	12.3	459	4	US-09-328-352-4648	Sequence 2, Appli
26	67.5	12.3	902	1	US-08-701-846-2	Sequence 2, Appli

6 Gaps 31; Indels 27; Mismatches 9; Insertions 1;

65 QTAALYNQAGCGVAHTRF-GSSARACNP---FGW 95
413 HIAA-----DGSVYNRYPGFKEKAANALKDIYGW 441

RESULT 2

```
Sequence 8, Application US/08622191A
; Patent No. 6612602
; GENERAL INFORMATION;
; APPLICANT: Sheen, Jen
; APPLICANT: Jyan-chyun
; TITLE OF INVENTION: PLANT SUGAR SENSORS AND USES THEREOF
; FILE REFERENCE: 007986/5070001
; CURRENT APPLICATION NUMBER: US/08/622,191A
; CURRENT FILING DATE: 1996-03-25
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 486
; TYPE: PRT
; ACQUAINT: Saccharomyces cerevisiae
```

ALIGNMENTS

Query Match 13.7%; Score 75.5; DB 4; Length 486;
 Best Local Similarity 30.2%; Pred. No. 1.7;
 Matches 29; Conservative 9; Mismatches 27; Indels 31; Gaps 6;

Qy 8 FSVITVMM--LIMASENVNGSAFTWSPGCGNNRERYSKGGCSAIIHQGGYDSESYTG 64
 Db 369 FGINNTVQERKLRLSELIGA-----RAARLSVGIAACIQRGYK--TG 412

Qy 65 QTAALYNNQAGCGSYVAHTRP-GSSARACNP---PGW 95
 Db 413 HIAA-----DSVINYNPFGFKEKANALIYGW 441

RESULT 3
 US-07-872-678A-48 Application US/07172678A
 Patent No. 5541060

GENERAL INFORMATION:
 APPLICANT: Bell, Graeme, et al.
 TITLE OF INVENTION: DETECTION OF EARLY-ONSET
 TITLE OF INVENTION: NON-INSULIN-DEPENDENT DIABETES MELLITUS
 NUMBER OF SEQUENCES: 48

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Arnold, White & Durkee
 STREET: Post Office Box 4433
 CITY: Houston
 STATE: Texas
 COUNTRY: USA
 ZIP: 77210

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patient Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/07172678A
 FILING DATE: 22-APRIL-1992
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Coughlin, Daniel F.
 REGISTRATION NUMBER: 36,111
 REFERENCE/DOCKET NUMBER: ARCD016
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 713-787-1400
 TELEX: 79-0924-713-789-2679

INFORMATION FOR SEQ ID NO: 48:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 486 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)

US-07-872-678A-48

Query Match 13.5%; Score 74.5; DB 1; Length 486;
 Best Local Similarity 39.3%; Pred. No. 2.2;
 Matches 24; Conservative 4; Mismatches 18; Indels 15; Gaps 4;

Qy 40 RAERYSKGGCSAIIHQGGYDSESYTGQTAALYNNQAGCGSYVAHTRP-GSSARACNP---FG 94
 Db 391 RAARLSVGIAACIQRGYK--TGHIA-----DGSVSTRYPGFKEKAANALKDYG 440

Qy 95 W 95
 Db 441 W 441

RESULT 5
 US-09-672-810-2 Application US/09672810
 Sequence 2, Application US/09672810
 GENERAL INFORMATION:
 APPLICANT: STOCKER, PENNY J.
 APPLICANT: STEINEL-CRESPI, DOROTHY T.
 APPLICANT: CRESPI, CHARLES L.
 TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
 FILE REFERENCE: G0307/7018

CURRENT APPLICATION NUMBER: US/09-672-810-2
 CURRENT FILING DATE: 2000-09-28
 PRIOR APPLICATION NUMBER: US 60/155,921
 PRIOR FILING DATE: 1999-08-28
 PRIOR APPLICATION NUMBER: US 60/158,818
 PRIOR FILING DATE: 1999-10-12

RESULT 4
 US-08-714-741-44 Application US/08714741
 Sequence 44, Application US/08714741
 Patent No. 6500613
 GENERAL INFORMATION:

NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO: 2
; LENGTH: 1280
; TYPE: PRT
; ORGANISM: Macaca fascicularis
US-09-672-810-2

Query Match Score 71; DB 4; Length 1280;
Best Local Similarity 25.5%; Pred. No. 19;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LPFSVITYMMLIAMSMEV----NGSAFTWSPGCGNNRAEYRSKGGCSAIHOKGGYD 59
Db 334 VFFSVLGAFTSVQASPSIEAPANARGAFREIKIDNKPSIDSYSKGHKPDNIGMLE 393

QY 60 -----ESV-----
Db 394 FRNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGCC 431

RESULT 6
•US-09-672-810-4
; Sequence 4, Application US/09672810
; Patent No. 6617450
; GENERAL INFORMATION:
; APPLICANT: STOCKER, PENNY J.
; APPLICANT: STEINEL-CRESPI, DOROTHY T.
; APPLICANT: CRESPI, CHARLES L.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7018
; CURRENT APPLICATION NUMBER: US/09/672,810
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,921
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 60/158,818
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO: 4
; LENGTH: 1283
; TYPE: PRT
; ORGANISM: Macaca fascicularis
US-09-672-810-4

Query Match Score 71; DB 4; Length 1283;
Best Local Similarity 25.5%; Pred. No. 19;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LPFSVITYMMLIAMSMEV----NGSAFTWSPGCGNNRAEYRSKGGCSAIHOKGGYD 59
Db 337 VFFSVLGAFTSVQASPSIEAPANARGAFREIKIDNKPSIDSYSKGHKPDNIGMLE 396

QY 60 -----ESV-----
Db 397 FRNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGCC 434

RESULT 7
•US-09-252-991A-30166
; Sequence 30166, Application US/09252991A
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: AERUGINOSA AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196,136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27

RESULT 8
•US-09-248-796A-17049
; Sequence 17049, Application US/09248796A
; Patent No. 674,137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al.
; TITLE OF INVENTION: NUCLEAR ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICANS
; FILE REFERENCE: 107196,132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO: 17049
; LENGTH: 491
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-17049

Query Match Score 69; DB 4; Length 491;
Best Local Similarity 39.4%; Pred. No. 9,8;
Matches 13; Conservative 8; Mismatches 12; Indels 0; Gaps 0;

QY 40 RAERYSKCCGSATHOKGGYDTSVTGTAALYNO 72
Db 398 RSARPSVCGIAACQREGYKTHCAADGSVTK 430

RESULT 9
•US-09-672-810-7
; Sequence 7, Application US/09672810
; Patent No. 6617450
; GENERAL INFORMATION:
; APPLICANT: STOCKER, PENNY J.
; APPLICANT: STEINEL-CRESPI, DOROTHY T.
; APPLICANT: CRESPI, CHARLES L.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7018
; CURRENT APPLICATION NUMBER: US/09/672,810
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,921
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/158,818
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO: 7
; LENGTH: 1280
; TYPE: PRT
; ORGANISM: Canis familiaris

RESULT 10
 US-09-672-810-7
Query Match 12.5%; Score 69; DB 4; Length 1280;
Best Local Similarity 25.5%; Pred. No. 32; Mismatches 33; Indels 28; Gaps 3;
Matches 25; Conservative 12; Gaps 3;
 Qy 6 LFFSVTVMMLIAMASEMV----NGSAFTVWSPGPNCNRARYSKCGCSAITHQKGGYD 59
 :|||: :|||: :|||:
 *Db 335 VFFSVLIGAFSICQASPSLEAFANARGAAYEIKIDNPKPSIDSYSKGHKPDNIKGNL 394
 Qy 60 ----FSY-----TGQAAALYNQAGC 75
 .Db 395 FKVTHFSYSPSRKEYKILKGLNLKVQSGQTVALVGNSGC 432

RESULT 11
 US-09-672-725C-4
Sequence 4, Application US/09672725C
Patent No. 6753177
GENERAL INFORMATION:
APPLICANT: Stocker, Penny J.
APPLICANT: Steimel-Crespi, Dorothy T.
APPLICANT: Crespi, Charles L.
APPLICANT: Rieff, Timothy C.
APPLICANT: Patten, Christopher J.
TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
FILE REFERENCE: G0307/7017
CURRENT APPLICATION NUMBER: US/09/672,725C
PRIOR APPLICATION NUMBER: US 60/156,510
PRIOR FILING DATE: 1999-09-28
NUMBER OF SEQ ID NOS: 32
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO 4
LENGTH: 1280
TYPE: PRF
ORGANISM: Canis familiaris
 US-09-672-725C-4

Query Match 12.5%; Score 69; DB 4; Length 1280;
 Best Local Similarity 25.5%; Pred. No. 32; Mismatches 33; Indels 28; Gaps 3;
 Matches 25; Conservative 12; Gaps 3;

Qy 6 LFFSVTVMMLIAMASEMV----NGSAFTVWSPGPNCNRARYSKCGCSAITHQKGGYD 59
 :|||: :|||: :|||:
 *Db 335 VFFSVLIGAFSICQASPSLEAFANARGAAYEIKIDNPKPSIDSYSKGHKPDNIKGNL 394
 Qy 60 ----FSY-----TGQAAALYNQAGC 75
 .Db 395 FKVTHFSYSPSRKEYKILKGLNLKVQSGQTVALVGNSGC 432

RESULT 12
 US-09-672-725C-2
Sequence 2, Application US/09672725C
Patent No. 6753177
GENERAL INFORMATION:
APPLICANT: Stocker, Penny J.
APPLICANT: Steimel-Crespi, Dorothy T.
APPLICANT: Crespi, Charles L.
APPLICANT: Rieff, Timothy C.
APPLICANT: Patten, Christopher J.
TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
FILE REFERENCE: G0307/7017
CURRENT APPLICATION NUMBER: US/09/672,725C
PRIOR APPLICATION NUMBER: US 60/156,510
PRIOR FILING DATE: 1999-09-28
NUMBER OF SEQ ID NOS: 32
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO 2
LENGTH: 1281
TYPE: PRF
ORGANISM: Canis familiaris
 US-09-672-725C-2

Query Match 12.5%; Score 69; DB 4; Length 1281;
 Best Local Similarity 25.5%; Pred. No. 32; Mismatches 33; Indels 28; Gaps 3;

Qy 6 LFFSVTVMMLIAMASEMV----NGSAFTVWSPGPNCNRARYSKCGCSAITHQKGGYD 59
 :|||: :|||: :|||:
 *Db 335 VFFSVLIGAFSICQASPSLEAFANARGAAYEIKIDNPKPSIDSYSKGHKPDNIKGNL 394
 Qy 60 ----FSY-----TGQAAALYNQAGC 75
 .Db 395 FKVTHFSYSPSRKEYKILKGLNLKVQSGQTVALVGNSGC 433

RESULT 13
 US-09-672-725C-23
Sequence 23, Application US/09672725C
Patent No. 6753177
GENERAL INFORMATION:
APPLICANT: Stocker, Penny J.
APPLICANT: Steimel-Crespi, Dorothy T.
APPLICANT: Crespi, Charles L.
APPLICANT: Rieff, Timothy C.
APPLICANT: Patten, Christopher J.
TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
FILE REFERENCE: G0307/7017
CURRENT APPLICATION NUMBER: US/09/672,725C
PRIOR APPLICATION NUMBER: US 60/156,510
PRIOR FILING DATE: 1999-09-28
NUMBER OF SEQ ID NOS: 32
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO 23
LENGTH: 1281

; LENGTH: 1281
 ; TYPE: PRT
 ; ORGANISM: Canis familiaris
 US-09-672-725C-23

Query Match 12.5%; Score 69; DB 4; Length 1281;
 Best Local Similarity 25.5%; Pred. No. 32;
 Matches 25; Conservative 33; Indels 28; Gaps 3;
 Mismatches 33; Insertions 28; Gaps 3;

Query Match 12.5%; Score 69; DB 4; Length 1281;
 Best Local Similarity 25.5%; Pred. No. 32;
 Matches 25; Conservative 12; Mismatches 33; Insertions 28; Gaps 3;

Query Match 12.5%; Score 69; DB 4; Length 1281;
 Best Local Similarity 25.5%; Pred. No. 32;
 Matches 25; Conservative 12; Mismatches 33; Insertions 28; Gaps 3;

Query 6 LFFSVITVMMLJAMASEMV-----NGSAFTVWSGPGNRAERYSKCGCSAIHQGGYD 59
 Db 336 VFFSVLIGAFSIGQASPSIEAFANARGAAYEFLKILDKNPIDSYSKSGHKPDNIKGNL 395

Qy 60 -----FSY-----TGQTAALYNGGC 75
 Db 396 FKNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGC 433

Search completed: November 5, 2004, 21:56:30
 Job time : 45 secs

RESULT 14
 Sequence 25, Application US/09672725C

; Paten No. 6753177

; GENERAL INFORMATION:

; APPLICANT: Stocker, Penny J.
 ; APPLICANT: Steimel-Crespi, Dorothy T.
 ; APPLICANT: Crespi, Charles L.
 ; APPLICANT: Rief, Timothy C.
 ; APPLICANT: Patten, Christopher J.
 ; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
 ; FILE REFERENCE: G0307/2017
 ; CURRENT APPLICATION NUMBER: US/09/672,725C
 ; CURRENT FILING DATE: 2000-09-28
 ; PRIOR APPLICATION NUMBER: US 60/156,510
 ; PRIOR FILING DATE: 1999-09-28
 ; NUMBER OF SEQ ID NOS: 32
 ; SOFTWARE: FastSEQ for Windows Version 3.0
 ; SEQ ID NO 25
 ; LENGTH: 1281

; TYPE: PRT
 ; ORGANISM: Canis familiaris

US-09-672-725C-25

Query Match 12.5%; Score 69; DB 4; Length 1281;
 Best Local Similarity 25.5%; Pred. No. 32;
 Matches 25; Conservative 33; Indels 28; Gaps 3;

Query Match 12.5%; Score 69; DB 4; Length 1281;
 Best Local Similarity 25.5%; Pred. No. 32;
 Matches 25; Conservative 12; Mismatches 33; Insertions 28; Gaps 3;

Query Match 12.5%; Score 69; DB 4; Length 1281;
 Best Local Similarity 25.5%; Pred. No. 32;
 Matches 25; Conservative 12; Mismatches 33; Insertions 28; Gaps 3;

Query Match 12.5%; Score 69; DB 4; Length 1281;
 Best Local Similarity 25.5%; Pred. No. 32;
 Matches 25; Conservative 12; Mismatches 33; Insertions 28; Gaps 3;

Query 6 LFFSVITVMMLJAMASEMV-----NGSAFTVWSGPGNRAERYSKCGCSAIHQGGYD 59
 Db 336 VFFSVLIGAFSIGQASPSIEAFANARGAAYEFLKILDKNPIDSYSKSGHKPDNIKGNL 395

Qy 60 -----FSY-----TGQTAALYNGGC 75
 Db 396 FKNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGC 433

RESULT 15
 US-09-672-725C-27

Sequence 27, Application US/09672725C

; Paten No. 6753177

; GENERAL INFORMATION:

; APPLICANT: Stocker, Penny J.
 ; APPLICANT: Steimel-Crespi, Dorothy T.
 ; APPLICANT: Crespi, Charles L.
 ; APPLICANT: Rief, Timothy C.
 ; APPLICANT: Patten, Christopher J.
 ; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
 ; FILE REFERENCE: G0307/2017
 ; CURRENT APPLICATION NUMBER: US/09/672,725C
 ; CURRENT FILING DATE: 2000-09-28
 ; PRIOR APPLICATION NUMBER: US 60/156,510
 ; PRIOR FILING DATE: 1999-09-28
 ; NUMBER OF SEQ ID NOS: 32
 ; SOFTWARE: FastSEQ for Windows Version 3.0
 ; SEQ ID NO 27

